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Summary 
 
Dissolution studies on various dosage forms (powder, tablets, teabags and alginate beads) of 
the Artemisia afra freeze dried aqueous extract (FDAE) all exhibit a rapid release profile. 
Generally, such a release profile may be therapeutically undesirable as it may affect 
absorption and hence the therapeutic outcome. In addition, also associated with rapid release 
profiles, is frequent dosing required (to maintain therapeutic plasma concentrations) and 
unavoidable fluctuations in plasma drug concentrations, leading to under and or over dosing. 
Based on the aforementioned shortcomings, there may be need to modify the dissolution 
profile of the phytoconstituents of A. afra. Phytosomes, which are complexes of 
phospholipids with phytoconstituents, offer a very viable dosage form option for A. afra as 
they could afford advantages of increased lipophilicity hence a decreased dissolution rate and 
improved absorption or permeability of the phytoconstituents. 
 
The objectives of this study were to; (1) prepare and characterise an A. afra freeze dried 
aqueous extract and the phytosomes thereof, (2) determine factors that influence the complex 
formation efficiency (CFE) between phytoconstituents and phosphatidylcholine in the 
preparation of A. afra phytosomes and (3) compare the phytoconstituent release properties, in 
terms of dissolution profiles, of FDAE versus the phytosomes, in simulated gastric and 
intestinal fluid, using luteolin as the marker compound. It was hypothesised that (1) the 
phytosome drug delivery technology can be successfully used on the A. afra FDAE to 
produce phytosomes with acceptable pharmaceutical physiochemical characteristics; (2) A. 
afra phytoconstituents in the phytosome complex are more lipophilic than the 
phytoconstituents in the FDAE and therefore the phytosome complex has a higher apparent 
solubility in n-octanol and (3) the dissolution rate of phytoconstituents from the FDAE is 
higher than that of phytoconstituents from the A. afra phytosomes. 
 
To realise these objectives, an A. afra freeze dried aqueous extract was prepared and 
characterised. Then, using a 23 full factorial experimental design, different batches of 
phytosomes were prepared from the FDAE to establish the factors that affected the complex 
formation efficiency. The independent variables investigated were stirring speed, type of 
organic solvent and mass ratio of FDAE to phospholipids, and the dependent variable was 
complex formation efficiency. From the experimental design results, the optimised 
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preparation variables were used to prepare phytosomes which were then characterised in 
terms of pharmaceutical physicochemical parameters. Finally, the dissolution profiles of the 
FDAE and the phytosomes were determined in simulated gastric (pH 1.2) and intestinal (pH 
6.8) fluids and compared using Q-release values, mean dissolution time values and 
mathematical models. 
 
A moderate yield (26.16 ± 2.90%) of the FDAE was obtained and the extract had good 
aqueous solubility, acceptable moisture content (2.47 ± 0.15%), a high flavonoid content 
(34.1 ± 6.4 mg QE/g) and contained moderate levels of the selected marker compound, 
luteolin (1.92 ± 0.01 µg/mg), mostly in the conjugate form (76.6%). However, the FDAE was 
hygroscopic and poorly lipid soluble (log P < 2). 
 
The solvent evaporation mechanical dispersion method was suitable for the preparation of A. 
afra phytosomes and yielded phytosomes with a moderately good complex formation 
efficiency (21.2 to 68.7%). Results from the experimental design showed that the complex 
formation efficiency was significantly affected by the phosphatidylcholine amount 
(p = 0.0049) and stirring speed (p = 0.0086), where the CFE varied directly with the former 
and inversely with the latter. Furthermore, the phytosomes possessed suitable pharmaceutical 
physicochemical characteristics with smooth, spherical, mono-dispersed (PDI = 0.201 ± 
0.076), nano-sized particles (487 ± 35 nm) which had good colloidal stability (-54.6 
± 0.2 mV) and significantly improved lipid solubility (p = 0.001). Lastly, comparison of the 
dissolution profiles of the FDAE versus phytosomes exhibited significantly 
different (p < 0.05) Q75 values, of 16 and 366 minutes, respectively, and mean dissolution 
time values of 18.9 and 269.4 minutes, respectively. Also, the release mechanisms of luteolin 
from the FDAE and phytosomes were dissimilar with release from the former being by 
Fickian diffusion and from the latter by a complex mechanism. 
 
In summary, the results showed that phytosome technology can be successfully used on the 
freeze dried aqueous extract of A. afra to modify the release of phytoconstituents from the 
extract. Moreover, the technique is also capable of producing phytosomes with acceptable 
pharmaceutical physicochemical properties suitable for drug delivery.  
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Chapter 1 
 
Introduction 
The use of herbal products in the management of various ailments has gained popularity in 
recent years. With the advancements in herbal product technology, plant-based drugs have 
received substantial attention from the medical community as well as patients (Barnes et al., 
2004; Capasso et al., 2000). Despite the increased attention, the clinical use of herbal 
products is however often still limited due to the poor oral bioavailability of the bioactive 
phytoconstituents, which typically have high molecular weights, poor aqueous or lipid 
solubility, and low plasma membrane permeability (Teng et al., 2012; WHO, 2004).  This 
challenge has encouraged researchers to formulate these phytoconstituents in delivery forms 
that improve the ease of administration, ensure sufficient bioavailability and have desirable 
aesthetic properties. The development of modern drug delivery systems for phytoconstituents 
has therefore become an essential element of pharmaceutical research. 
 
In recent years, the technique of complexing plant extracts with phospholipids to produce 
phytosomes, a drug delivery system, has emerged as one of the most successful methods to 
improve the delivery of hydrophilic and hydrophobic phytoconstituents (Khan et al., 2013). 
Indeed, this drug delivery system i.e. phytosomes, has been used to improve the 
biopharmaceutical properties of herbal extracts, leading to enhanced bioavailability 
(Bombardelli, 1991; Bombardelli et al., 1989; Habbu et al., 2013; Kidd, 2009; Yanyu et al., 
2006; Yue et al., 2010), modified release (Khan et al., 2013; Singh et al., 2012) and 
improved stability (Khan et al., 2014; Saraf, 2010) of phytoconstituents.  Examples of such 
successful commercial phytosomal herbal products on the market include Silybin 
Phytosome™, Green Tea Phytosome™ and Ginkgo Biloba Phytosome™ (Bhattacharya, 
2009; Dhir et al., 2016; Karimi et al., 2015). The phytosome delivery system has also been 
extended to conventional drugs such as aspirin (Semalty et al., 2010c), diclofenac 
(Khazaeinia & Jamali, 2003), aceclofenac (Semalty et al., 2010a) and rifampicin (Singh et 
al., 2014), but generally, the technique’s main application remains in the delivery of plant 
phytoconstituents. 
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Artemisia afra (common names; African wormwood; wilde-als; umhlonyane) is a medicinal 
plant widely used in southern Africa for numerous ailments, including colds, coughs, diabetes 
mellitus, heartburns, bronchitis and asthma among others (Watt & Breyer Brandwijk, 1962; 
Van Wyk & Gericke, 2000). Chemical analyses conducted on extracts of A. afra have 
reported the species to contain acetylenes, coumarins, flavonoids, terpenoids and volatile oils 
(Van Wyk & Gericke, 2000; Watt & Breyer Brandwijk, 1962; Avula et al., 2009; Asfaw et 
al., 2005). However, most of these bioactive constituents, especially flavonoids and their 
glycosides (Willcox, 2009; Mukinda et al., 2010; Tikiso, 2015), are water-soluble and limited 
in their effectiveness because of poor absorption and bioavailability when taken orally 
(Komperlla, 2004; Manach et al., 2004; Khan et al., 2013; Nkengla, 2014) and this may be a 
significant problem if the aqueous liquid or dried extracts of A. afra are used. 
 
Indeed, various dosage forms (e.g. powder, tablets, teabags and alginate beads) of the A. afra 
freeze dried aqueous extract (FDAE) have thus far been made which all exhibited a rapid 
dissolution profile (Komperlla, 2004; Dube, 2006; Max, 2007; Nkengla, 2014), characteristic 
of water-soluble phytoconstituents. However, as Costa and colleagues (2011) have 
highlighted, such rapid phytoconstituent release and dissolution may be therapeutically 
undesirable as it may affect absorption and hence the therapeutic outcome (Costa et al., 
2011). Also, with such products frequent dosing is then required to maintain therapeutic 
plasma concentrations and unavoidable fluctuations in drug concentrations which may, in 
turn, lead to under and or over dosing. Thus there may be a need to modify the rapid 
dissolution profile of the FDAE phytoconstituents. 
 
Phytosomes may also be a very viable dosage form option to help solve these problems 
associated with A. afra FDAE. It could help increase the lipophilicity, decrease the 
dissolution and release rate, and improve absorption or cellular permeability of the water 
soluble phytoconstituents of this widely used herbal (traditional) medicine.  
 
Given the aforementioned arguments, the main objectives of the present study were to (i) 
prepare and characterise an A. afra freeze dried aqueous extract and the phytosomes thereof, 
(ii) determine factors that influence the complex formation efficiency (CFE) between 
phytoconstituents and phosphatidylcholine in the preparation of A. afra phytosomes, and (iii) 
compare the phytoconstituent release properties, in terms of dissolution profiles, of FDAE 
versus the phytosomes, in simulated gastric and intestinal fluid, using luteolin as the marker 
http://etd.uwc.ac.za/
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compound. It was hypothesised the phytosome preparation method would yield phytosomes 
having acceptable physicochemical pharmaceutical characteristics and that the dissolution 
rate of phytoconstituents (using luteolin as a marker compound) from the phytosomes would 
be less than that of the freeze dried aqueous extract. 
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Chapter 2 
 
Literature Review 
             
 
2.1 Introduction 
In this chapter, the herbal drug delivery phytosome system is discussed, including the various 
preparation methods and characterisation techniques. An overview of the pharmacognostic 
aspects of Artemisia afra and the shortcomings of its oral dosage formulations are detailed. 
Finally, a review of dissolution methods and methods for dissolution profile comparisons are 
also be presented. 
 
2.2 Drug delivery of herbal products 
Herbal products have gained immense attention and access to the medicine markets 
throughout the globe as safer and effective substitutes of modern synthetic medicines which 
are considered to be full of adverse and toxic interactions. In under developed and developing 
nations all over the world plant drugs in traditional forms have been supposed to satisfy the 
primary healthcare needs of about 80% of the population and even in developed nations these 
medicines are being utilized by about 65% of the population (Khan et al., 2013).  
 
However, the bioavailability of the plant phytoconstituents has become an issue of concern 
for researchers because many of them have poor oral bioavailabilities, specifically those 
containing polyphenolic rings in their structures which are water soluble such as flavonoids, 
terpenoids and tannins (Manach et al., 2004). The reasons for the poor bioavailability of these 
substances are low aqueous or lipid solubility, high molecular weight/size and poor plasma 
membrane permeability (Karakaya, 2004; Manach et al., 2005; Teng et al., 2012). Moreover, 
orally administered plant extracts are also subject to degradation or destruction in the 
presence of gastric fluids (Bhattacharya, 2009). This has therefore restricted the use of 
pharmacologically effective polyphenolic plant actives for treating various disorders. 
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In order to address these challenges and enhance the effectiveness of herbal therapy several 
novel delivery systems have been trialled in the recent time. These delivery systems include 
liposomes, niosomes and transfersomes (Pandita & Sharma, 2013) with liposomal 
formulations being the most popular. 
 
2.2.1 Phytosomes 
These are sometimes referred to as pharmacosomes, naturosomes or phospholipid-complexes. 
In recent years, the technique of complexing plant drugs with phospholipids has emerged as a 
challenging but one of the most successful methods for improving bioavailability and 
therapeutic efficacy of a number of poorly absorbed plant constituents. This technique uses 
phospholipid molecules containing phosphatidylcholine in their structure to form complexes 
(phytosomes) with standardized herbal extracts and/or the specific active pharmaceutical 
ingredient of the plant. As a result, the phytosome complex improves the membrane 
permeability, oil-water partition coefficient and hence the systemic bioavailability of these 
drugs (Raju, Reddy & Reddy, 2011; Loguercio et al., 2012). 
 
Incorporation of water soluble drugs into phospholipid complexes considerably enhances 
bioavailability of the phytoconstituents by increasing penetration through the lipoidal plasma 
membrane while the phospholipid complexation of poorly water soluble drugs, increases 
bioavailability by improving solubility in gastric fluids (Shivanand & Kinjal, 2010; Saraf, 
2010). The phyto-phospholipid complexation technique in recent years has made it possible 
to administer highly efficacious plant actives with an improved biological profile.  
 
Some of the advantages of phyto-phospholipid complexes over pure plant drugs are presented 
in (Figure 2.1). 
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Figure 2.1: Advantages of phytosomal drug delivery system (Khan et al., 2013) 
 
2.2.2 Background of phytosomes 
Phytosomes were first developed by Indena® in 1988, an Italian nutraceutical company 
(Indena®, 2016; Simms, Quinn & Wendel, 2000). Within the framework of their studies, 
after observation that phospholipids had a marked affinity for flavonoids, they developed a 
new series of compounds designated “Phytosome®” which were essentially complexes from 
the complexation of polar botanical derivatives and phospholipids. These complexes were 
considered to be novel entities on the basis of their physicochemical and spectroscopic 
characteristics. Their characterisation revealed that they were solid lipophilic substances, with 
a defined melting point, freely soluble in aprotic solvents, moderately soluble in fats and 
insoluble in water. Interestingly, when treated with water the phytosomes assumed a micelle 
arrangement, similar to that of liposomal dispersions. 
 
However, due to the close similarity of phytosomes and liposomes, it is important to 
structurally clearly differentiate the two (Figure 2.2) 
 
http://etd.uwc.ac.za/
7 
 
 
Figure 2.2: Comparison between liposomes and phytosomes (Indena®, 2016) 
 
The fundamental difference is that in liposomes the active principle is the aqueous cavity 
enclosed by the phospholipids whereas in the phytosome the active principle is an integral 
part of the phospholipid through molecular interactions. The aforementioned structural 
differences are the basis of the advantages of the phytosomes over the liposomes. For 
instance, due to the presence of molecular interactions in phytosomes, the complex is more 
stable than the liposome which is mainly prone to structural leakages (Singh et al., 2011a). 
Also, on the basis of the chemical bonds present in the phytosome, the improved 
bioavailability is more pronounced than that with liposomes. The natures of the interactions 
present in the phytosome complex are dealt with in detail in the next section. 
 
2.2.3 Phytoconstituent - phospholipid interactions 
Phytoconstituents interact uniquely with phospholipid molecules through chemical bonds 
with them. This has been established by characterisation techniques involving (Nuclear 
magnetic resonance (NMR), differential scanning calorimetry (DSC) and Fourier transform 
infrared (FT-IR) spectroscopy, where analysis of drug–phospholipid complexes were 
compared with respect to analyses of pure drug and their physical mixture with phospholipids 
(Bombardelli et al., 1989; Bombardelli, 1991).  
 
Bombardelli and colleagues (1989) thoroughly characterised the catechin–phospholipid 
complex using the aforementioned techniques. They found in the 1H-NMR that signals from 
protons belonging to the flavonoid moiety were so broad that the protons could not be 
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revealed. For the phospholipid there was broadening of all signals, while the singlet 
corresponding to N-(CH3)3 of choline underwent an extensive up-field shift. And in the 
13C-
NMR spectra, all the flavonoid carbons were practically invisible, signals corresponding to 
the glycerol and choline portion of the phospholipid broadened and some shifted while most 
resonances of the fatty acid chains retained their original sharp lines shape.  
 
All the mentioned physical and physicochemical features, revealed a strong interaction 
between the flavonoid molecule and the polar head of the phospholipid, with the two 
aliphatic chains wrapped around the flavonoid to produce a lipophilic envelope that allows 
the complex to dissolve in low polarity solvents. Moreover, inspection of the Dreiding 
molecular models supports this hypothesis as the average length of flavonoids was 13Ao 
which fitted well with the polar region of the lipid, while the two C18 carbon fatty acid 
chains sufficiently enclosed the complex (Bombardelli et al., 1989). A molecular 
representation of the complex is shown in Figure 2.3.  
 
Figure 2.3: Schematic of phytosome molecular complex (Kidd, 2009) 
 
Indirect evidence of the formation of the complex was confirmed through FT-IR and DSC 
(Bombardelli, 1991). The FT-IR spectra of the complex, physical mixture and pure drug were 
all unique thus revealing an interaction as per NMR results. Similarly, DSC thermograms of 
the previously mentioned samples were also different from each other thus also confirming 
formation of the complex. 
  
The interaction has been attributed to formation of hydrogen bond and/or hydrophobic 
interaction between the two molecules (Bombardelli et al., 1989; Bombardelli, 1991; Pathan 
& Bhandari, 2011). The -OH group of phenolic rings existing in the structure of the drug 
molecule is suggested to be involved in the formation of hydrogen bonding and the formation 
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of Vander Waals forces between the two moieties has also been suggested by some 
researchers in studies on phospholipid complexes of luteolin (Khan et al., 2014), Centella 
extract (Saoji et al., 2016), tetrandrine (Zhao et al., 2013) and rutin (Das & Kalita, 2014).  
  
2.2.4 Preparation methods 
Various methods are used for production of phytosomes including anti-solvent precipitation 
(Maiti et al., 2007; Semalty et al., 2010b; Gupta & Dixit, 2011; Arora, Sharma & Kaur, 2013; 
Habbu et al., 2013; Keerthi, Pingali & Srinivas, 2014; Saoji et al., 2016), solvent evaporation 
(Yanyu et al., 2006; Sikarwar et al., 2008; Zhao et al., 2013; Keerthi, Pingali & Srinivas, 
2014; Khan et al., 2014; Yue et al., 2010), precipitation (Singh et al., 2012) and anhydrous 
co-solvent lyophilization (Awasthi, Kulkarni & Pawar, 2011). The main methods, namely, 
anti-solvent and solvent evaporation, will be discussed.  
 
2.2.4.1 Solvent evaporation 
In the solvent evaporation method, the drug and the phospholipids are placed in the same 
flask containing a suitable solvent system such as tetrahydrofuran or ethanol or in separate 
flasks with different organic solvents. The reaction is allowed to be carried out by sonication, 
refluxing or stirring at suitable fixed temperature for a fixed duration of time to get maximum 
possible yield and drug entrapment. The solvent is then evaporated under vacuum or at room 
temperature to yield a residue which is then flushed with nitrogen gas. In a modified form of 
the solvent evaporation technique, Sikarwar et al. formulated marsupsin–phospholipid 
complex using mechanical dispersion oriented liquid anti-solvent precipitation process 
(Sikarwar et al., 2008). They dissolved soy lecithin in diethyl ether by sonication and 
marsupsin in double distilled water. The drug solution was then added drop-wise to the 
phospholipid solution with sonication.  The resultant formulation was then refrigerated and 
on analyzing the complex showed 44% entrapment of marsupsin. 
 
2.2.4.2 Anti-solvent precipitation 
The traditional anti-solvent precipitation technique is the most utilised by many researchers. 
It incorporates n-hexane as the anti-solvent to precipitate out the drug–phospholipid complex 
from the organic solvent (Maiti et al., 2007; Semalty et al., 2010b; Gupta & Dixit, 2011). In 
this method, both the plant extract/active and phospholipids are dissolved in the same solvent, 
and refluxed for a fixed time at a fixed temperature resulting in a clear solution. To this clear 
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solution, n-hexane is then added to precipitate the phytosomes which are either filtered and 
flushed with nitrogen gas or simply just left to dry in a desiccator. 
 
2.2.4.3 Preparation parameters and variables 
There are numerous preparation parameters and variables that affect the characteristics of the 
final phytosomal products. These include, but are not limited to: preparation method, type 
and purity of phospholipids, type of organic solvents used, ratio of drug to phospholipids, 
stirring speed (depending on preparation method), reaction time and concentration of 
reactants. Only a few of these are discussed in the proceeding sections. 
 
2.2.4.3.1 Type of phospholipids 
Phospholipids are indispensable components of all cellular and sub-cellular membranes, they 
can arrange as bilayer membranes. They are widely distributed in humans, animals and 
plants. 
 
These molecules possess a hydrophilic head group and hydrophobic acyl chains are linked to 
an alcohol. The variation in head groups, aliphatic chains and alcohols leads to the existence 
of a wide variety of phospholipids. Examples include phosphatidylcholine, 
phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine, sphingolipids and 
cardiolipin, which are predominantly found in eukaryotic cell membranes (Li et al., 2015).  In 
addition, the different sources of phospholipids also enhance the species of phospholipids. 
Various phospholipids, such as soybean phosphatidylcholine, egg phosphatidylcholine, or 
synthetic phosphatidylcholine, as well as hydrogenated phosphatidylcholine, are commonly 
used in different types of formulations. 
 
Phosphatidylcholine and phosphatidylethanolamine are most abundantly present in the lipid 
fraction of most biological membranes and they mainly constitute the matrix of these 
membranes. Table 2.1 shows the percentage contributions of different lipids in the 
mammalian cell membrane. 
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Table 2.1: Contribution of different lipids in typical phospholipid structure (Khan et al., 
2013) 
Lipid  Sub-type Percentage contribution 
Glycerolipids 
 
 
 
Sphingolipids 
 
Sterols 
Phosphatidylcholine 
Phosphatidyl ethanolamine 
Phosphatidyl inositol 
Phosphatidyl serine 
Sphingomyelin 
Glycosphingolipids 
Cholesterol 
45–55 
15–25 
10–15 
5–10 
5–10 
2–5 
10–20 
 
Phospholipids are amphipathic molecules having considerable solubility in aqueous and oily 
mediums. They have a polar and a non-polar portion in their structures (Acharya, Parihar & 
Acharya, 2011).  Naturally occurring phospholipids incorporate an unsaturated fatty acid 
(such as oleic acid, linoleic acid or arachidonic acid) in position 2 and a saturated one (such 
as stearic acid or palmitic acid) in position 1. The most commonly used phospholipids 
(Figure 2.4) are those derived from soya bean containing higher proportions that is about 
76% of phosphatidylcholine with a high content of polyunsaturated fatty acids like linoleic 
acid about 70%, linolenic acid and oleic acid (Scholfield, 1981). 
 
 
Figure 2.4: Different fatty acids constituting phosphatidylcholine (Khan et al., 2013) 
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Lastly, phytosomes formed using lower purity grades of phospholipids are greasy in nature 
and form large aggregates while those prepared using lipids of more than 90% purity grade 
show susceptibility to degradation due to oxidation, which affects complex stability. So, 80% 
purity grade is the commonly used phospholipid grade (Pandita & Sharma, 2013). 
 
2.2.4.3.2 Solvents used in the preparation of phytosomes 
In contrast to the phospholipids, where phosphatidylcholine is the main lipid used in the 
preparation of phytosomes, a wide range of solvents have been used as reaction mediums for 
formulating phytosomes. 
 
Aprotic solvents such as tetrahydrofuran (Yue et al., 2010; Zhao et al., 2013), 
dichloromethane (Maiti et al., 2007; Semalty et al., 2010c; Arora, Sharma & Kaur, 2013; 
Habbu et al., 2013; Keerthi, Pingali & Srinivas, 2014), diethyl ether and chloroform (Mali et 
al., 2014) have been used. However, of late, protic solvents, especially ethanol (Yanyu et al., 
2006; Peng et al., 2010; Pathan & Bhandari, 2011; Khan et al., 2014; Saoji et al., 2016) have 
largely replaced the use of the aprotic solvents. Though most preparation techniques involve 
the use of a single solvent, several authors have used mixed solvent systems whereby the 
phospholipids are dissolved in a different solvent from that of the drug/extract. Mixed solvent 
systems utilised include methanol and dichloromethane (Das & Kalita, 2014), diethyl ether 
and water (Sikarwar et al., 2008) and dichloromethane and ethanol (Keerthi, Pingali & 
Srinivas, 2014). 
 
Lastly, in as far as the anti-solvent preparation method is concerned; the precipitation of the 
phytosomes has almost exclusively been mediated by n-hexane, as previously stated. 
 
2.2.4.3.3 Ratio of drug to phospholipids 
Complexation of phytoconstituents and phospholipids has been performed in varying 
mass/molar ratios varying from 1:0.5 to 1:3. In most research works, a stoichiometric ratio of 
1:1 has been considered most suitable for the preparation of the complex (Jena et al., 2014; 
Semalty et al., 2010c; Arora, Sharma & Kaur, 2013; Changediya, Khadke & Devdhe, 2011; 
Gandhi et al., 2012). Khan et al, Saoji et al, Pathan and Bhandari, and, Yue et al optimised 
the preparation method of luteolin, Centella extract, embelin and oxymatrine phospholipid 
complexes, respectively (Khan et al., 2014; Yue et al., 2010; Saoji et al., 2016; Pathan & 
http://etd.uwc.ac.za/
13 
 
Bhandari, 2011). All authors noted that an increase in the phospholipid content resulted in an 
increase in the encapsulation efficiency, with their optimal ratios of drug to phospholipid 
being 1:2.33, 1:3, 1:3 and 1:3, respectively. On the contrary, Qin et al also performed an 
optimisation study and obtained an optimal ratio of 1:0.9 (Qin et al., 2010). These conflicting 
findings therefore suggest that optimal ratios actually vary depending on the particular 
drug/extract and probably other factors such as preparation method and solvents used.   
 
2.2.5 Characterisation techniques 
Methods of characterisation of phytosomes for use immediately after preparation and upon 
storage are required for adequate quality control of the product. The methods have to be 
reproducible, precise and rapid, in the context of their use in the industrial setting.  
 
2.2.5.1 Complex formation efficiency 
This is also referred to as encapsulation/entrapment efficiency or drug entrapment. It is a very 
critical characteristic of the final complex as it reflects the suitability of the preparation 
method and the various preparation parameters and variables. Drug content is usually 
quantified by UV spectrophotometry (Sikarwar et al., 2008; Keerthi, Pingali & Srinivas, 
2014; Das & Kalita, 2014) or by HPLC (Jena et al., 2014; Pathan & Bhandari, 2011). The 
two main methods used in the determination of the CFE are the direct and indirect methods. 
There are several variations of these methods, some of which are highlighted below. 
 
Both methods generally involve centrifugation to separate the complexes from the 
uncomplexed constituents in the medium. In the direct method, the final phytosomes in solid 
form are solubilised by an aprotic solvent such as chloroform or protic solvent such as 
methanol so as to release the phytoconstituents from the complex. Alternatively, in the case 
of phytosomes prepared from the anti-solvent technique which yields phytosomes in the solid 
form inclusive of the uncomplexed drug, the mixture can be dissolved in an aprotic solvent 
such as chloroform that selectively dissolves the complex while the uncomplexed drug 
sediments (Saoji et al., 2016). The CFE can therefore be determined by analysis of the drug 
content in the supernatant.  
 
In contrast, with the indirect method, the amount of uncomplexed drug is determined by 
analysis of the supernatant, after centrifugation (Das & Kalita, 2014). The 
http://etd.uwc.ac.za/
14 
 
encapsulated/complexed drug can be determined by removing the supernatant, washing the 
pellet and then either lysing the pellet with a surfactant such as Triton X-100 or simply 
dissolving the pellet in an organic solvent such as methanol/ethanol (Peng et al., 2010). A 
more accurate indirect method involves determination of total drug in the suspension by 
lysing the suspension with a surfactant.  
 
2.2.5.2 Particle analysis (particle size and distribution) 
The average size and size distribution of phytosomes are important parameters which have 
effects on the overall performance of the product. Drug dissolution rate, absorption rate, 
dosage form content uniformity and stability are all, to varying degrees, dependent on particle 
size, size distribution and interactions of solid surfaces (Aulton & Taylor, 2013). In many 
cases, for both drugs and additives, particle size reduction is required to achieve the desired 
physiochemical characteristics.  
 
Several methods exist for the determination of particle size but the main methods used in 
phytosome formulations are dynamic light scattering (DLS) and scanning electron 
microscopy. The DLS is the most popular for this use as it is a non-invasive, well-established 
technique for measuring the size and size distribution of molecules and particles typically in 
the submicron region and, with the latest technology, lower than 1nm. The technique 
measures Brownian motion (random movement of particles in a liquid due to the 
bombardment by the molecules that surround them) and relates this to the size of the 
particles. It does this by illuminating the particles with a laser and analysing the intensity 
fluctuations in the scattered light (Malvern Instruments, 2004). 
 
2.2.5.3 Colloidal stability 
The magnitude of the zeta potential is an indication of the potential stability of the colloidal 
system. A colloidal system is when one of the three states of matter: gas, liquid and solid, are 
finely dispersed in one of the others. For this technique the main states of interest are of: a 
solid dispersed in a liquid, and a liquid dispersed in a liquid, i.e. an emulsion. The zeta 
potential is determined by calculating the electrophoretic mobility. The electrophoretic 
mobility is determined by performing an electrophoresis experiment on the sample and 
measuring the velocity of the particles using Laser Doppler Velocimetry (LDV) (Malvern 
Instruments, 2016). 
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2.2.5.4 Particle surface morphology 
Transmission electron microscopy (TEM) or Scanning electron microscopy (SEM) can be 
used to visualize the phytosome. These techniques can be utilised for studying the surface 
order of the complexes. The purity grades of the lipid being used and few variables observed 
during operation (method of preparation, vacuum assigned and rotational speed) alter the 
shape and size of phytosomes. 
 
2.2.5.5 Partition coefficient 
If a third substance is added to a system of two immiscible liquids in equilibrium, the added 
component will distribute itself between the two liquid phases until the ratio of its 
concentrations in each phase attain a certain value: the distribution constant or partition ratio. 
The octanol–water distribution ratio, Ko/w, is the accepted physicochemical property 
measuring the hydrophobicity of chemicals (Sangster, 1997). The technique can also be used 
to evaluate the solubilities and apparent solubilities of substances. 
 
2.2.5.6 Complexation confirmatory analyses 
Part of the characterisation of the phytosomes involves confirmatory analyses which verify 
complexation between the phytoconstituents and phospholipids. One such analysis, NMR, 
has been discussed in detail in section 2.2.3 and will therefore be excluded from this section. 
Other techniques, FT-IR and DSC, also highlighted in section 2.2.3, will be briefly discussed. 
  
2.2.5.6.1 Spectroscopic properties 
This can be determined by FT-IR and has been described in section 2.2.3. Comparison 
between the spectrum of the complex and spectrum of the individual components and their 
mechanical mixtures confirms the complex formation by infrared spectroscopy. 
 
2.2.5.6.2 Thermal analysis 
Determination of this characteristic has been described in section 2.2.3. DSC thermal analysis 
apparatus measures the temperature variation of physical properties of a sample against time 
(Haynie, 2001). In other words, the instrument determines the temperature and heat flow 
associated with material transitions as a function of time and temperature (Haines, Reading & 
Wilburn, 1998). During a change in temperature, DSC measures the amount of heat, which is 
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radiated or absorbed by the sample by measuring the difference in temperature between the 
sample and reference (Haynie, 2001; Haines, Reading & Wilburn, 1998). 
 
2.2.5.6.3 Crystalline nature 
The crystalline nature of drug can be determined using X-ray powder diffraction technique. 
The method hinges on the generation of X-rays which are focused on the sample. The sample 
then diffracts the rays and these are detected (Dutrow & Clark, 2014).  A pivotal aspect of all 
diffractions, is the angle between the incident and reflected rays, which can be regulated 
through the scan angle. The overall combined intensity of all reflection peaks is projected by 
area under curve of X-ray powder diffraction pattern that specifies the product properties 
(Pandita & Sharma, 2013). 
 
2.3 Artemisia afra: An overview 
This section covers the pharmacognostic aspect of the species where the taxonomy, 
geographical distribution, traditional uses, pharmacological activity and phytochemical 
composition are reviewed. In addition, the various dosage formulations of the extract and 
their shortcomings are also reviewed. 
 
2.3.1 Taxonomy (Tropicos, 2016) 
Family: Asteraceae Bercht. & J. Presl  
Family homonym: Compositae Giseke  
Genus: Artemisia L.     
Species: Artemisia afra Jacq. Ex Willd.  
Common names: Wild wormwood, African wormwood and Wilde-als (Patil, Dass & 
Chandra, 2011)  
Indigenous South African names: Umhlonyane (Xhosa), Mhlonyane (Zulu), Lanyana (Sotho) 
and Lengana (Tswana) (Burits, Asres & Bucar, 2001) 
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Figure 2.5: Artemisia afra plant 
 
2.3.2 Distribution 
The species grows in the South and Eastern regions of the African continent and has been 
located in Ethiopia, Kenya, Namibia, Tanzania, Democratic Republic of Congo, Zambia, 
Zimbabwe, Angola and the Republic of South Africa (Watt & Breyer Brandwijk, 1962; Liu, 
Van der Kooy & Verpoorte, 2009). 
 
2.3.3 Traditional uses of A. afra 
The species is administered in a variety of ways including as enemas, poultices, infusions, 
body washes and lotions and smoked, snuffed or drunk as a tea for the treatment and 
management of various ailments (Patil, Dass & Chandra, 2011). 
 
2.3.3.1 Use in respiratory tract related conditions 
The A. afra species is primarily used in common cold, cough, sore throat, influenza and 
asthma (Watt & Breyer Brandwijk, 1962; Graven et al., 1990; Hutchings et al., 1996; Van 
Wyk & Wink, 2004). The leaves are heated and the vapours inhaled to alleviate symptoms of 
colds and flu (Watt & Breyer Brandwijk, 1962; Bhat & Jacobs, 1995). It is also used to clear 
the blocked nasal passage by inserting fresh leaves in the nostrils or by using as snuff; to 
relieve pain in the throat in scarlet fever, either the hot infusion being used as gargle or the 
throat exposed to vapors (Watt & Breyer Brandwijk, 1962; Taylor et al., 2001). The leaves 
are also smoked by some tribes to help release phlegm, to ease and soothe a sore throat and 
coughing at night (Roberts, 1990). For cold and chest problems in infants, fresh leaves are 
placed in a flannel bag and hung around baby’s neck (Van Wyk, De Wet & Van Heerden, 
2008). 
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2.3.3.2 Other traditional uses of A. afra 
The species is also used in several other conditions which include gynaecological, 
gastrointestinal, topical, pyretic and inflammatory ailments. Gynaecological ailments include 
dysmenorrhea (Van Wyk & Gericke, 2000), amenorrhea and menstrual cramps (Steenkamp, 
2003).  Gastrointestinal ailments include indigestion, colic, constipation, flatulence, gastritis, 
dry dyspepsia and intestinal worms infestations (Jansen, 1981; Buchbauer & Silbernagel, 
1989; McGaw, Jäger & Van Staden, 2000; Van Wyk & Wink, 2004).  
 
Watt and Brandwiijk reported topical use of the species where the extract is applied topically 
to ease the pain and hasten bursting of boils, carbuncles, large acne pimples; hot baths in 
which the decoction is used to bring out the rash in measles, mumps, chicken pox and an 
infusion or decoction is used to bathe haemorrhoids, herpes and venereal sores (Watt & 
Breyer Brandwijk, 1962). 
 
Other miscellaneous uses include that in rheumatism (Burits, Asres & Bucar, 2001), gout 
(Van Wyk & Wink, 2004), fever (Watt & Breyer Brandwijk, 1962; Fowler, 2006), malaria 
(Fowler, 2006), epilepsy (Yineger et al., 2008), haematuria and to alleviate stabbing pain 
(Abebe & Ayehu, 1993), as anti-fertility agent (Desta, 1994), in diabetes mellitus (Watt & 
Breyer Brandwijk, 1962; Deutschländer, Lall & Van De Venter, 2009) and in tinea captitis 
(Abebe & Ayehu, 1993). 
 
Besides its beneficial medicinal properties, the A. afra species may also be used by the 
communities as a preservative in food stuffs (Muyima et al., 2002; Ashebir & Ashenafi, 
1999). In addition, it can be used as an insecticide to reduce pest pressure on crops which is 
achieved by planting it as a border surrounding vegetable plants and crops (Patil, Dass & 
Chandra, 2011). 
 
2.3.3.3 Pharmacological actions of A. afra 
Despite the traditional uses, researches have gone on to establish the in vitro pharmacological 
activity of the species. Activities reported include anti-fungal and anti-bacterial (Graven et 
al., 1992; Libbey & Sturtz, 1989; Mangena & Muyima, 1999), anti-diabetic (Afolayan & 
Sunmonu, 2011; Sunmonu & Afolayan, 2013), bronchodilatory (Mulubwe, 2007; Mjiqiza, 
Syce & Obikeze, 2013), anti-cancer (Fouche et al., 2008; Nibret & Wink, 2010), anti-
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inflammatory (Ntutela et al., 2009), anti tuberculotic (Ntutela et al., 2009), anti-spasmolytic 
(Mulatu & Mekonnen, 2007) and anti-malarial (Liu et al., 2010) activities. 
 
2.3.4 Phytochemical constituents of Artemisia afra 
Artemisia afra is rich in phytoconstituents, non-volatile and volatile secondary metabolites. 
These are shown in Tables 2.2 and 2.3. 
 
Table 2.2: Volatile A. afra phytoconstituents 
 Constituent References 
Monoterpenoids e.g. artemisia alcohol, artemisia 
ketone, camphor, 1,8-cineole, 
limonene, β-thujone 
(Chagonda, Makanda & Chalchat, 
1999; Burits, Asres & Bucar, 2001; 
Muyima et al., 2002; Viljoen et al., 
2006; Asekun, Grierson & 
Afolayan, 2007; Vagionas et al., 
2007) 
Sesquiterpenes Bicycloelemene, α-bisabolol, β-
caryophyllene, germacrene D-4-ol, 
β-selinene, (Z)-β-farnesene 
(Chagonda, Makanda & Chalchat, 
1999; Viljoen et al., 2006) 
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Table 2.3: Non-volatile A. afra phytoconstituents 
 Constituent References 
Sesquiterpenes β-farnesene (Jakupovic et al., 1988) 
Triterpenes α-amyrin, β-amyrin, friedelin, 
squalene 
(Silbernagel, Spreitzer & 
Buchbauer, n.d.; Jakupovic et al., 
1988) 
Coumarins Ouebrachitol, umbelliferone 
derivatives, scopoletin, isofraxidin, 
12-hydroxy-α-cyperone 
(Goodson, 1922; Bohlmann & 
Zdero, 1972; Jakupovic et al., 1988) 
Glaucolides artemisia glaucolide, 1α-
hydroxyafraglaucolide, 12-hydroxy-
α-cyperone 
(Jakupovic et al., 1988) 
Guaianolides 11,13-dehydromatricarin, 
guaianolides 3 (11 derivatives), 
guaianolides 1 (2 derivatives) 
(Jakupovic et al., 1988; Kraft et al., 
2003) 
Flavonoids Acacetin, apigenin, chrysoeriol, 
diosmetin, genkwanin, 7-
methoxyacacetin, quercetin, 
kaempferol, tamarixetin, luteolin 
(Wollenweber & Mann, 1989; Tang 
et al., 2000; Kraft et al., 2003; 
Waithaka, 2004; Avula et al., 2009) 
 
2.3.5 Selection of chemical marker compounds for herbal product quality control 
The European Medicines Agency (EMEA) defines chemical markers as chemically defined 
constituents or groups of constituents of a herbal medicinal product which are of interest for 
quality control purposes regardless of whether they possess any therapeutic activity (Li et al., 
2008). The EMEA further classified the chemical markers into active markers which are 
constituents or groups of constituents known to contribute to therapeutic activities and 
analytical markers which are the constituents or groups of constituents that serve solely for 
analytical purposes. 
 
An ideal chemical marker should exhibit therapeutic effects of the herbal medicinal product. 
Herbals have a multitude of compounds but only a limited number have been shown to 
possess pharmacological activity and as such other chemical components that may not exhibit 
pharmacological effects may also be employed as markers (Li et al., 2008). In the case of 
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Artemisia afra the flavonoids have been shown to be partially responsible for the therapeutic 
activity of the extract (Mukinda et al., 2010) and, of particular interest, luteolin which has 
been identified in sizeable quantities compared to the other flavonoids (Waithaka, 2004). 
 
2.3.5.1 The flavonoids 
Flavonoids belong to a vast group of polyphenolic compounds that are widely distributed in 
all plants. Plant polyphenols have been of interest to scientists for decades, originally owing 
to their importance in plant physiology, specifically for their roles in plant pigmentation and 
flavour. Polyphenols are involved in plant growth and reproduction, provide resistance to 
pathogens and predators, and protect crops from disease and pre-harvest seed germination 
(Ross & Kasum, 2002). Recently, interest in the possible health benefits of polyphenols 
(particularly flavonoids) has increased owing to their antioxidant and free-radical scavenging 
abilities observed in vitro. 
 
 
Figure 2.6: Basic structure of flavonoids 
 
They are produced as the result of the secondary metabolism of plants and are frequently 
found attached to sugars (glycosides), thus tending to be water-soluble. Occasionally, 
polyphenols also occur in plants as aglycones. 
 
Flavonoids can be divided into eight subclasses based on their molecular structure (Figure 
2.6). The structure of the subclasses differ in their arrangement of hydroxyl, methoxy and 
glycosidic side groups and in the conjunction between A and B rings (Sandhar et al., 2011). 
A variation in C ring provides division of subclasses. The six major subclasses of flavonoids 
include the flavones (e.g., apigenin, luteolin), flavonols (e.g., quercetin, myricetin), 
flavanones (e.g., naringenin, hesperidin), catechins or flavanols (e.g., epicatechin, 
gallocatechin), anthocyanidins (e.g., cyanidin, pelargonidin), and isoflavones (e.g., genistein, 
daidzein). 
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Figure 2.7: The six major subclasses of flavonoids (Lakhanpal & Rai, 2007) 
 
Flavonols and flavones are the most widely occurring flavonoids; of these luteolin, quercetin, 
kaempferol, myricetin, chrysin and apigenin are widely distributed. The flavanones, 
flavanols, dihydroflavones and dihydrochalcones, are considered minor flavonoids because of 
their limited natural distribution (Di Carlo et al., 1999) 
 
Most herbal medicinal plant materials including A. afra, are usually prepared as aqueous-
based decoctions and infusions. In these formulations, different active phytoconstituents such 
as the aqueous-soluble flavonoid glycoside compounds will be released. Thus, the flavonoid 
glycosides represent the form in which actives from many traditional medicinal products 
(such as A. afra) are released when prepared for oral consumption, and are inherently more 
abundant than the poorly aqueous soluble flavonoid aglycones. These flavonoid glycosides, 
due to their hydrophilicity, are generally poorly absorbed (Ross & Kasum, 2002; Manach et 
al., 2004). 
 
Despite their abundance, it is difficult to quantify individual flavonoid glycosides due to their 
inherently large number in plant samples.  However these glycosides are derived from a 
limited number of flavonoid aglycones, and have actually been described as “sustained-
release natural pro-drugs of their aglycones”(Chao, Hsiu & Hou, 2002). 
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Due to their abundance, glycosides, in quantification studies are usually acid-hydrolysed to 
the aglycones (Figure 2.8) and glycoside levels quantified in terms of the aglycone content. 
 
Figure 2.8: Illustration of flavonoid glycoside hydrolysis 
 
Several analytical techniques are available for the identification, separation and quantification 
of the flavonoid aglycones, the most commonly used being chromatographic methods e.g. 
HPLC (Komperlla, 2004; Dube, 2006; Max, 2007; Avula et al., 2009; Nkengla, 2014). 
 
2.4 Dissolution 
Dissolution is defined as the transfer of molecules or ions from a solid state into solution 
(Aulton & Taylor, 2013). Dissolution studies are an indispensable tool to assess quality and 
predict to some extent the absorption and bioavailability of the actives and consequently, the 
therapeutic outcome of a drug (or pharmaceutical) product (or dosage form). Drug absorption 
from solid dosage forms after oral administration depends on the release of the drug 
substance from the drug product, the dissolution or solubilisation of the drug under 
physiological conditions, and the permeability across the gastrointestinal tract. Because of the 
critical nature of the first two of these steps, in vitro dissolution may be relevant to the 
prediction of in vivo performance. 
 
2.4.1 Dissolution of herbal products 
Dissolution testing is the customary measure of release from a dosage form. The technique 
has been applied to herbal products and the focus has been extended to its use in the 
prediction of bioavailability and bioequivalence. (Wang et al., 2015). 
 
Guidelines for dissolution testing of oral dosage forms for orthodox medicines have been 
developed by the Food and Drug Administration (FDA) (FDA, 1997). However, the 
application of such guidelines to herbal products is not so straight forward. For the vast 
majority of the herbal products, there are no compendial methods on dissolution. Also, 
because of their multi-component nature whereby they consist of numerous phytoconstituents 
which may be active or may have a synergistic effect on each other, the selection of a suitable 
http://etd.uwc.ac.za/
24 
 
marker compound can be quite complicated. This, coupled with the general lack of 
standardisation of these herbal products, results in large variations in the quality and quantity 
of active components in such products.  
 
The complexity associated with the selection of a marker compound is evident in a study by 
Nair and Kanfer on the release of hypoxoside and sterols from African potato (Hypoxis 
hemerocallidea) commercial products. The authors, using the USP basket apparatus, reported 
a minimum of 75% release of hypoxoside and sterols in one hour, in dissolution studies 
conducted at pH 1.2 and fed state simulation fluid at pH 5.0,  respectively (Nair & Kanfer, 
2008). Due to the different physicochemical characteristics of the marker compounds, 
different dissolution media had to be utilised thus complicating the standardisation of a 
dissolution method for the plant extract. 
 
Despite such difficulties, dissolution tests can of course clearly show differences in herbal 
products and/ dosage forms. For instance, in one of the few studies done so far, dissolution 
tests on Passiflora products demonstrated 50% and almost 100% dissolution of actives from 
capsules containing the powder and capsules containing the extract, respectively, in 10 
minutes (USP paddle method at a speed of 50 rpm, using water at 37 ± 0.5°C and UV 
spectrophotometric detection at 340 nm) (Costa et al., 2011). 
 
2.4.1.1 Dissolution of Artemisia afra formulations 
Several pharmaceutical dosage forms of A. afra have been investigated. These include tablets 
(Komperlla, 2004), encapsulated FDAE (Max, 2007), tea bags (Dube, 2006) and alginate and 
polymethylmethacrylate coated FDAE (Nkengla, 2014). The tablet and encapsulated 
formulations were subjected to compendial dissolution methods in water and pH 1.2 buffer, 
respectively. Both authors reported rapid/immediate release profiles for their preparations 
with more than 75% of the luteolin marker compound released with 45 minutes. The infusion 
study on the tea bag also revealed a similar release profile. In addition, although the release 
study was conducted in a beaker, the alginate and polymethylmethacrylate forms of the A. 
afra FDAE, interestingly also showed an immediate release profile in pH 6.8 medium where 
over 75% of the marker compound was released within 30 minutes. This was not expected as 
these polymers should be able to modify the release profile of the constituents.  
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The above-mentioned rapid release profiles are however disadvantageous as they can result in 
sharp increases in drug concentrations potentially leading to toxic levels (Freiberg & Zhu, 
2004). Also, the therapeutic levels are poorly maintained as frequent re-administration is 
required to maintain the therapeutic plasma levels. Costa et al. also highlighted the 
undesirability of rapid release profiles, suggesting that in some instances, e.g. herbal 
products, it may be necessary to determine whether the organism is capable of readily 
absorbing all the active principles released at the beginning of the dissolution process without 
affecting the therapeutic outcome (Costa et al., 2011). Modification of the release of the 
phytoconstituents of A. afra will greatly assist in reducing the dosing frequency and amount, 
produce more reproducibility, uniform drug release and absorption, reduction of local 
irritations and reduced dose dumping (Das et al., 2015). These are all characteristics that may 
be attained through complexation of the phytoconstituents with phospholipids. 
 
2.4.1.2 Dissolution of phospholipid-complexes (phytosomes) 
Several studies on the dissolution of phytosomes have been conducted (Yanyu et al., 2006; 
Semalty et al., 2010c; Arora, Sharma & Kaur, 2013; Jena et al., 2014; Keerthi, Pingali & 
Srinivas, 2014; Saoji et al., 2016). Various dissolution parameters were used including 
different volumes ranging from 500 – 900 ml, stirring speeds 50 – 100 rpm, dissolution 
apparatus USP type I or II, dissolution media pH 1.2 - 7.4 and durations of dissolution tests 
ranging from 2 – 12 hours. Most studies were conducted in a phosphate buffer medium at pH 
6.8. Interestingly most of the dissolution profiles showed approximately a 100% release after 
about 12 hours. Arora et al., described the dissolution profile of their phytosomal tablet 
formulation as sustained release (Arora, Sharma & Kaur, 2013), which was similar to that of 
most phospholipid complex dissolution studies. 
 
Of note, in all these phospholipid-complex dissolution studies, the objective of complexation 
was to improve aqueous solubility of poorly-water soluble constituents hence in all the 
studies there is improved dissolution efficiency. Here, the authors utilised the amphiphilic 
nature of phospholipids which render the characteristic to the constituents. Incipiently, 
development of phytosomes was mainly targeted at improving lipophilicity of hydrophilic 
constituents so as to improve bioavailability. According to the innovator of the technique 
these complexes are insoluble in water (Bombardelli, 1991), which is contrary to the findings 
of the dissolution studies. This may be explained by the fact that complexing hydrophilic 
constituents will result in a complex with significantly less aqueous solubility whereas 
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complexation of a hydrophobic constituent results in a complex with improved water 
solubility properties. All this is attributed to the amphiphilic nature of the phospholipids. 
 
2.4.2 Development of dissolution methods 
The absorption of a drug is controlled/determined by its dissolution such that differences in 
dissolution profiles are indicative of different bioavailabilities, which in turn can lead to 
variations in the therapeutic and toxic effects (Ngo, 2007). It is therefore important that in the 
development of a dissolution method, the conditions in the gastrointestinal tract, where the 
dissolution and absorption occur, are closely mimicked. 
 
The USP suggests that for botanicals, compliance with dissolution testing is performed by 
testing six or more dosage units individually in each vessel and measuring one or more index 
marker compounds or the extract specified in the individual monograph (Nair & Kanfer, 
2008).  
 
Typical media for dissolution may include the following: diluted hydrochloric acid; buffers 
(phosphate or acetate) in the physiologic pH range of 1.2–7.5; simulated gastric or intestinal 
fluid (with or without enzymes) and water. For some drugs, incompatibility of the drug with 
certain buffers or salts may influence the choice of buffer. The molarity of the buffers and 
acids used can influence the solubilising effect, and this factor may have to be evaluated. 
 
For poorly soluble drugs, a percentage of a surfactant may be added to the aqueous solutions 
(acidic or buffer solutions) to enhance the solubility of the drug. FDA approved surfactants 
include, but are not limited to, sodium dodecyl sulfate (SDS), sodium lauryl sulfate (SLS), 
polysorbates 20 and 80, cetyltrimethylammonium bromide (CTAB), lauryl dimethylamine 
oxide and polyoxyethylene lauryl ether (Brij35) (U.S. Food and Drug Administration, 2016). 
The surfactants selected for the solubility investigations should cover all common surfactant 
types, i.e., anionic, nonionic, and cationic. When a suitable surfactant has been identified, 
different concentrations of that surfactant should be investigated to identify the lowest 
concentration needed to achieve sink conditions. Typically, the surfactant concentration is 
above its critical micellar concentration (CMC) (USP 36, 2004). 
 
For compendial Apparatus 1 (basket) and Apparatus 2 (paddle), the volume of the dissolution 
medium used can vary from 500 to 1000 ml, with 900 ml as the most common volume. The 
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choice of apparatus is based on knowledge of the formulation design and the practical aspects 
of dosage form performance in the in vitro test system. In general, a compendial apparatus 
should be selected. For solid oral dosage forms, Apparatus 1 and Apparatus 2 are used most 
frequently. When Apparatus 1 or Apparatus 2 is not appropriate, another official apparatus 
may be used. 
 
Apparatus 1 (baskets) at 50–100 rpm or Apparatus 2 (paddles) at 50 or 75 rpm are used most 
commonly. Other agitation speeds are acceptable with appropriate justification. Rates outside 
25–150 rpm for both the paddle and the basket are usually not appropriate because of mixing 
inconsistencies that can be generated by stirring too slow or too fast. Agitation rates between 
25 and 50 rpm are generally acceptable for suspensions. 
 
2.4.3 Methods for comparison of dissolution profiles 
Another important area in dissolution data analysis is assessment of the similarity between 
dissolution profiles. Several approaches have been developed for comparing dissolution 
profiles. The main methods for comparing dissolution profiles are shown in Table 2.4. 
 
Table 2.4: Categories of methods to compare dissolution profiles (Polli et al., 1997) 
Approach  Method    Parameter/equation   
ANOVA based Multivariate ANOVA    - 
   Multiple univariate ANOVA   - 
Model-independent Ratio test procedures   Ratio percentage dissolved 
        Ratio of AUC(dissolution curves) 
        Ratio of mean dissolution time 
   Pair-wise procedures   Difference factor (f1) 
        Similarity factor (f2) 
        Index of Rescigno (ξ1 and ξ2) 
Model-dependent See Table 2.5    See Table 2.5 
   
2.4.3.1 Model dependent methods for dissolution profile comparisons 
Model dependent methods (Table 2.5) for dissolution profile analysis and comparison attempt 
to determine the release of the active from a formulation by employing mathematical 
equations and use fitted models to describe dissolution and the kinetics of drug release from a 
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product in different areas of the gastrointestinal tract, each section signified by its appropriate 
dissolution medium. 
 
Table 2.5: Mathematical equations for models describing release of active 
pharmaceutical ingredient (API) from its matrix (Zhang et al., 2010) 
 
Model Equation Parameters  
Zero order F = k0*t k0 
First order with Fmax F = Fmax*[1 - Exp( - k1*t)] k1, Fmax 
Weibull_1 F = 100*{1-Exp[-((t-Ti)^β)/α]} α, β, Ti 
Weibull_2 F = 100*{1-Exp[-(t^β)/α]} α, β 
Weibull_3 F = Fmax*{1-Exp[-(t^β)/α]} α, β, Fmax 
Weibull_4 F = Fmax*{1-Exp[-((t-Ti)^β)/α]} α, β, Ti, Fmax 
Makoid-Banakar with 
Tlag 
F = kMB*(t-Tlag)^n*Exp[-k*(t-Tlag)] kMB, n, k, Tlag 
Peppas-Sahlin 1 with Tlag F = k1*(t-Tlag)^m+k2*(t-Tlag)^(2*m) k1, k2, m, Tlag 
Peppas-Sahlin 2 with Tlag F = k1*(t - Tlag)^0.5 + k2*(t - Tlag) k1, k2, Tlag 
Probit_2 F = Fmax*Ф[α+β*log(t)] Fmax, α, β 
Logistic_2 F=Fmax*Exp[α+β*log(t)]/{1+Exp[α+β*log(t)]} α, β, Fmax 
Logistic_3 F = Fmax/{1+Exp[-k*(t-γ)]} k, γ, Fmax 
Korsmeyer-Peppas F = kKP*t^n kKP, n 
Korsmeyer-Peppas with 
Tlag 
F = kKP*(t-Tlag)^n kKP, n, Tlag 
 
2.4.3.1.1 Zero order kinetics 
This is dissolution that occurs in dosage forms that do not disintegrate but release the drug 
slowly (assuming that area does not change and no equilibrium conditions are obtained). It 
may be represented mathematically by the equation below and graphically by Figure 2.9 
 
F = Kot     Eqn 2.1 
Where, F is the fraction of drug dissolved in time t and Ko is the zero order release constant.  
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Figure 2.9: Graphical representation of zero order release kinetics 
 
Zero order release kinetics is usually exhibited by modified release dosage forms, 
transdermal systems, matrix tablets and osmotic systems. These systems release a constant 
amount of drug per unit time which is ideal to achieve prolonged therapeutic effects (Costa & 
Lobo, 2001). 
 
2.4.3.1.2 First order kinetics 
Here, the rate of drug release is dependent upon the concentration gradient between the 
concentration in the static liquid layer next to the solid surface and concentration in the bulk 
medium at a time (t) (Singhvi & Singh, 2011). This release is represented by Equation 2.2 
below and Figure 2.10. 
 
F = 100 * [1 - e-k1*t]      Eqn 2.2 
Where k1 is the first order release constant. 
 
The dosage forms following this dissolution profile include water soluble drugs in porous 
matrices such that release of drug will be proportional to the amount of drug remaining in the 
matrix.  
 
Figure 2.10: Graphical representation of first order release kinetics 
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2.4.3.1.3 Weibull model 
This model has been successfully applied to almost all kinds of dissolution curves (Costa & 
Lobo, 2001). The model expresses the accumulated amount of drug (F) in solution at time (t) 
by the Equation 2.3 
    Eqn 2.3 
Where, α is a scale parameter that describes the time scale of the process, Ti represents the 
lag time before onset of dissolution. The term β, is a shape parameter that describes the shape 
of the curve as either exponential (β = 1) (Case 1), sigmoid (S-shaped) with upward curvature 
followed by a turning point (β > 1) (Case 2), or parabolic (β < 1) (Case 3), with a higher 
initial slope and after that consistent with the exponential. 
 
There are four different modifications of the Weibull model which generally differ in terms 
of the presence or absence of parameters such as Ti and Fmax. The model has been subject to 
criticism as it is an empiric model without any kinetic fundament that characterises the 
dissolution kinetic properties of the drug. But of late studies have shown that the β, can be 
used to as an indicator to describe the mechanism of release of the drug through a polymer 
matrix (Papadopoulou et al., 2006) (Table 2.6). 
 
Table 2.6: Interpretation of release mechanisms from polymeric systems using the 
Weibull function (Mbamalu, 2015) 
 
Time exponent, β  Solute release mechanism 
β ≤ 0.75   Fickian diffusion in fractal or Euclidian spaces 
0.75 < β  < 1  Combined release mechanism 
β > 1  Complex release mechanism 
 
2.4.3.1.4 Logistic models 
These are also empirical models, and lack significant kinetic properties. These models are 
valid only when the value of time t exceeds zero (Mbamalu, 2015). There are three variations 
of this model which relates the fraction F, of drug released at time t but for purposes of this 
study only Logistic models 2 and 3 (Logistic_2 and Logistic_3) will be described. They are 
represented by the respective Equations 2.4 and 2.5; 
http://etd.uwc.ac.za/
31 
 
 
F = Fmax . e[α + β*log(t)]   
1 + e[α + β*log(t)]    Eqn 2.4 
and, 
F = Fmax .  1  
{1+ e[ - k*(t - γ)]}    Eqn 2.5 
 
where, α is the scale factor and β is the shape factor in Logistic_2 model. In the Logistic_3 
model k is the shape factor, γ is the time at which F = Fmax/2 and Fmax is the maximum 
fraction of the drug released at infinite time.  
 
2.4.3.1.5 Peppas-Sahlin with Tlag 
Peppas and Sahlin in 1989 developed an equation that described drug release governed by 
diffusion and/ relaxation (Peppas & Sahlin, 1989). The Equations 2.6 and 2.7 describe the 
fraction, F, of drug released at time t; 
 
F = k1 * (t - Tlag)m + k2 * (t - Tlag)2m    Eqn 2.6 
and 
F = k1 * (t - Tlag)0.5 + k2*(t - Tlag)    Eqn 2.7 
where, k1 is the constant related to the Fickian kinetics, k2 is the constant related to Case-II 
relaxation kinetics, m (which usually ranges between 0 and 1) is the diffusional exponent for 
a device of any geometric shape which exhibits controlled release and Tlag is the lag time 
prior to drug release. These models differ from the original Peppas-Sahlin model, simply by 
the inclusion of the Tlag parameter. 
 
2.4.3.1.6 Makoid-Bakanar with Tlag 
The Makoid-Banakar function is represented by: 
F = kMB * (t - Tlag)n * e[-k * (t - Tlag)]   Eqn 2.8 
where, kMB, n and k are empirical parameters of the model. These parameters are limited by 
the fact that total drug /marker compound dissolution must occur at the same time as the 
maximum value of the Makoid-Banakar function (Pais, 2001). The Makoid-Banakar with Tlag 
model differs from the original Makoid-Banakar model by the inclusion of the parameter, 
Tlag, which represents the time before onset of drug release. 
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2.4.3.1.7 Korsmeyer-Peppas with Tlag 
This is a semi-empiric model that exponentially relates drug release to the time (t) elapsed. It 
was developed in by Korsmeyer and colleagues (Korsmeyer et al., 1983) and further 
modified by Peppas (Peppas, 1985). It has generally been used in the analysis of drug release 
from dosage forms where the mechanism of release is not well elucidated or the release 
involves more than one type of release mechanism. The generic equation is shown below 
 
Mt = k t n 
M∞        Eqn 2.9 
where Mt/ M∞ is the fraction of drug released, k is the rate constant and n is the release 
exponent. 
 
Peppas (1985) utilised the release exponent n, to characterise various release mechanisms 
depending on the shape of the dosage form, either slab e.g. circular flat topped tablets or 
cylindrical e.g. capsules. The interpretation of n for slabs was as follows; n = 0.5 represents 
Fickian diffusion and higher values of n, between 0.5 and 1.0, or n = 1.0 indicate mass 
transfers following non-Fickian diffusion. Table 2.7 describes the interpretation of the release 
exponent in polymeric systems which are cylindrical in shape. 
 
Table 2.7: Interpretation of the release exponent in cylindrical polymeric systems 
(Singhvi & Singh, 2011) 
Release exponent (n) Drug release mechanism Rate as a function of time 
0.45 Fickian diffusion t -0.5 
0.45 < n < 0.89 Anomalous transport t n - 1 
0.89 Case II transport Zero order release 
n > 0.89 Super Case II transport t n - 1 
 
Several models have been discussed but no model universally fits all the different types of 
dissolution/release data and it is therefore necessary to select the best model that best fits and 
describes the data.  
 
http://etd.uwc.ac.za/
33 
 
The most common method used to assess the fit of a model equation is the coefficient of 
determination, R2 (Costa & Lobo, 2001). It however has a weakness of the R2 increasing with 
an increase in the number of parameters in the model irrespective of the significance of the 
variable added to the model and hence it is only useful when comparing models with the 
same number of parameters. In order to compare models with different numbers of 
parameters, the adjusted coefficient of determination, R2adj, is used. The best model is 
selected based on the value of the R2adj, where the highest value indicates best fit. 
 
The Akaike Information Criterion (AIC) has become a standard tool in model fitting (Costa 
& Lobo, 2001). It measures goodness of fit based on maximum likelihood, where the model 
with best fit for a given set of data is the model with the lowest AIC value. This tool is only 
applicable in comparisons of models with similar weighting schemes. 
 
2.4.3.2 Model independent methods for dissolution profile comparisons 
As shown in Table 2.4, these can be further differentiated as ratio tests and pair-wise 
procedures. The ratio tests are relations between parameters obtained from the release assay 
of the reference formulation and the release assay of the test product at the same time and can 
range from a simple ratio of percent dissolved drug (t) to a ratio of area under the release or 
dissolution curve (AUC) or even to a ratio of mean dissolution time (MDT). 
 
The most commonly used pair-wise procedures are the difference factor and similarity factor 
(Moore & Flanner, 1996) and these are therefore now briefly discussed.  
The contrast between the two is that difference factor (f1) measures the percent error between 
two curves over all time points (Eqn 2.10) whereas the similarity factor (f2) is a logarithmic 
reciprocal square root transformation of one plus the mean squared (the average sum of 
squares) differences of drug percent dissolved between test and reference (Eqn 2.11) (Costa 
& Lobo, 2001). 
 
   Eqn 2.10 
 
where Rt and Tt are the mean percent dissolved at each time point for the reference and test 
products, respectively, and n is the number of observations /dissolution sample times being 
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considered for the computation. An f1 value between 0 and 15 indicates similarity of two 
dissolution profiles while values outside this range indicate dissimilarity. 
 
   Eqn 2.11 
 
where, the parameters, Rt, Tt and n are as described for the difference factor, f1 and Wt is an 
optional weight factor.  
 
The f2 is more sensitive than the f1 in the determination of dissolution profile similarity and is 
therefore the method of choice advocated by the FDA for purposes of the assessment of 
similarity between two in-vitro dissolution profiles. The similarity factor ranges from 0 to 
100, where 100 indicates the profiles are identical and 0 for dissimilar profiles. Limits for 
similarity are values between 50 and 100 whereas dissimilar profiles will be any value less 
than 50. The method is suitable for dissolution profile comparisons when there are more than 
3 dissolution time points.  
 
2.4.3.3 Statistical methods for dissolution profile comparisons 
The methods based on the analysis of variance can also be divided into two, viz. the one-way 
analysis of variance (ANOVA) and multivariate analysis of variance (MANOVA). These 
statistical methods assess the difference between the means of two drug release data sets in 
single time point dissolution (ANOVA or t-student test) or in multiple time point dissolution 
(MANOVA) (Zhang et al., 2010). 
 
These statistical methods may seem good for dissolution profile comparison of active 
compounds from herbal materials, where within batch variations may be quite significant, as 
it takes note of the within-batch variation in analysed samples. However, statistical methods 
for dissolution profiles comparison are not ideal as each dissolution time point is treated as a 
separate entity, independent of other points, which is not necessarily so. As such, the 
difference in profiles may be significant at some points and not at others, making 
interpretation difficult. 
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Moreover, ANOVA-based methods answer whether the profiles are statistically 
indistinguishable from each other but this does not necessarily equate to the profiles being 
pharmaceutically or practically indistinguishable.  
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Chapter 3 
 
Work Plan 
             
3.1 Introduction 
This chapter details the study objectives, hypotheses tested and the study approach 
implemented to meet the objectives. The chapter further elucidates rationales for, and 
approaches followed in, the different aspects of the study.  
 
3.2  Study objectives 
The overall objectives were to determine whether; 
1) phytosome technology could be successfully applied to A. afra to produce 
phytosomes possessing an acceptable pharmaceutical quality and, 
2) A. afra phytosomes prepared from the FDAE would have different dissolution 
properties of the phytoconstituents versus the extract.  
 
To realize these objectives, the following were to be done; 
(i) Preparation and characterisation of a FDAE of A. afra,  
(ii) Preparation of A. afra phytosomes from the FDAE using the solvent 
evaporation mechanical dispersion method, 
(iii) Determination of factors that influence the efficiency of complex formation 
between phytoconstituents and phosphatidylcholine in the preparation of A. 
afra phytosomes, 
(iv) Determination of physicochemical pharmaceutical characteristics (particle size 
and distribution, particle morphology, colloidal stability, apparent solubility) 
of A. afra phytosomes and 
(v) Comparison of the dissolution profiles of A. afra phytosomes versus the 
FDAE, in simulated gastric and intestinal fluid, using luteolin as the marker 
compound. 
 
3.3 Hypotheses 
The following hypotheses were to be tested; 
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Hypothesis 1: The drug delivery phytosome technology can be successfully used on 
the FDAE of A. afra to produce phytosomes having the following acceptable 
physiochemical pharmaceutical characteristics, i.e. 
 
    Poly dispersity index ≤ 0.2 
 
    -30 mV ≥ Zeta potential ≥ 30 mV 
 
Hypothesis 2: A. afra phytoconstituents in the phytosome complex (AAP) are more 
lipophilic than the A. afra FDAE phytoconstituents and therefore have a higher 
apparent solubility (AS) in octanol, i.e. 
 
ASoctAAP > ASoctFDAE 
 
And the converse; the FDAE phytoconstituents have a higher apparent solubility in water 
compared to the phytosome phytoconstituents, i.e. 
 
ASwaterAAP < ASwaterFDAE 
 
where, ASoctAAP and ASoctFDAE are the apparent solubilities, measured in terms of the marker 
compound luteolin, of phytosomes and FDAE in 1-octanol, respectively; and ASwaterAAP and 
ASwaterFDAE the apparent solubilities of the phytosomes and FDAE in water, respectively. 
 
Finally, usually increased lipophilicity results in a decrease in aqueous solubility, which 
directly results in a decrease in the dissolution rate (drug release). Therefore, the final 
hypothesis to be tested was: 
 
Hypothesis 3: The dissolution rate (D) of luteolin from the FDAE is higher than that 
of luteolin from the A. afra phytosomes, i.e. 
 
DFDAE > DAAP 
 
where, DFDAE and DAAP were the dissolution rates, based on levels of marker compound, 
luteolin, of FDAE and the phytosomes, respectively. 
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and  
 
    Q75 FDAE < Q75 AAP 
 
Where, Q75 FDAE and Q75 AAP is the time for 75% of the luteolin to be released into solution 
from the FDAE and phytosomes, respectively. 
 
3.4 Study approach 
The study questioned whether the phytosome drug delivery technology could be successfully 
applied to A. afra to produce phytosomes of an acceptable pharmaceutical quality and 
whether the A. afra phytosomes prepared from the FDAE would modify (decrease) the 
release properties of the extract’s phytoconstituents into physiologic fluids.  
 
In quest to answer these questions, firstly, an A. afra freeze dried aqueous extract was to be 
prepared. Then, from the FDAE, phytosomes were to be prepared based on a 23 full factorial 
experimental design to identify the factors that affect the efficiency of complex formation. In 
the phytosome preparation, the selected independent variables to be investigated included 
stirring speed, type of organic solvent and mass ratio of FDAE to phospholipids, and the 
dependent variable was the CFE (complex formation efficiency). From the results obtained, 
the optimised preparation variables were to be selected and used to prepare the final 
phytosomes and the latter characterised in terms of physicochemical pharmaceutical 
parameters such as particle size, morphology and shape, particle size distribution, colloidal 
stability and solubility. Subsequently, the dissolution tests were to be carried out in simulated 
gastric (pH 1.2) and intestinal (pH 6.8) fluids to determine and compare the phytoconstituent 
release profiles from the FDAE versus phytosomes, using luteolin as the selected marker 
compound. Lastly, statistical and model dependant and independent approaches were to be 
used to compare the dissolution profiles. 
 
3.4.1 Rationale for modifying the release properties of Artemisia afra 
phytoconstituents 
In a report on dissolution studies carried out on tea bags of the FDAE (Dube, 2006), the 
author described the release profile as ‘rapid’, with 85% of the constituents released within 
15 minutes, and in another study on encapsulated A. afra FDAE, the preparation was also 
http://etd.uwc.ac.za/
39 
 
described ‘rapidly dissolving’ (Max, 2007). This phytoconstituent release pattern was 
however fully expected since the FDAE was prepared by aqueous extraction and its actives, 
consequently, highly water soluble. 
 
However, as previously mentioned, the rapid phytoconstituent release is particularly 
problematic in circumstances where the active constituents are poorly absorbed, as is the case 
with A. afra (Komperlla, 2004). In addition, challenges associated with a rapid dissolution of 
poorly absorbed substances is that frequent dosing is required to maintain therapeutic plasma 
concentrations and unavoidable fluctuations in drug concentrations may lead to under and or 
over dosing. But a modification in the release profile was expected to result in a reduction of 
dosing interval, more reproducibility and uniform drug release and absorption, reduction of 
local irritations and minimal dose dumping (Das et al., 2015). All these considerations 
motivated the basis for the study. 
 
3.4.2 Why luteolin as marker compound? 
For this study and for several of the characteristics and parameters to be measured, a suitable 
marker compound had to be selected. Herbal products are generally quite complex, consisting 
of complex components that may be active individually or in combination. The “actives” are 
usually defined to be the whole herbal preparation, e.g. the extract in its entirety. For 
characterisation purposes the European Agency for the Evaluation of Medicinal Products 
(EMEA) proposes three categories of herbal medicinal products based on the characterisation 
of their active components  (Nair & Kanfer, 2008). Relevant to A. afra, Category A products 
consist of standardised extracts for which an active moiety/moieties has/have been 
definitively identified, and in this case, the flavonoid luteolin, as it has been identified to be 
partly responsible for the therapeutic activity of the extract (Mjiqiza, Syce & Obikeze, 2013; 
Tikiso, 2015). The aforementioned luteolin, has also been found to be the major flavonoid 
constituent in crude extracts of A. afra (Waithaka, 2004), several studies involving A. afra 
have successfully used it as a marker compound (Komperlla, 2004; Dube, 2006; Max, 2007; 
Nkengla, 2014; Tikiso, 2015) and finally, much is known on the extraction, detection and 
quantification of luteolin in plant matrices. All this thus made luteolin a most suitable marker 
compound to characterise A. afra preparations and for use in the present study. 
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Chapter 4 
 
Preparation and characterisation of Artemisia afra preparations: 
FDAE and phytosomes 
             
 
4.1 Introduction 
The overall goal of the work reported in this chapter was to test the hypothesis that 
phytosome drug delivery technology can be successfully used on Artemisia afra FDAE to 
produce phytosomes with acceptable pharmaceutical physicochemical characteristics. The 
equipment, materials and methods used to prepare and characterise Artemisia afra 
preparations are presented, and the results obtained reported and discussed. 
 
4.2 Equipment and materials 
 
4.2.1 Equipment 
The following equipment was used: 
 
-86°C ultralow freezer (Nuaire, Model NU 9668E, Nuaire, Japan), heating mantle 
(MRC, Model MN-500C), oven (Labotech, Model LDO-080F, DaihanLabotech Co 
Ltd, Korea), analytical balance (Ohaus, Model PA413, Ohaus Corporation, USA), 
square hot plate magnetic stirrer (Dragonlab, Model MS7-H550 Pro, Dragon 
Laboratories, China), ultrasonic bath (Scientech, Model 702, Labotec, South Africa), 
vortex mixer (KK, Model VM-300, Germany Industrial Corp, Taiwan), vacuum 
pump (Buchi, Model V-500, BuchiLarbotechnik AG, Switzerland), rotavapor (Buchi, 
Model R-11, BuchiLarbotechnik AG, Switzerland) connected to a vacuum pump 
(Buchi, Model V-700, BuchiLarbotechnik AG, Switzerland), centrifuge (Baxter, 13 
Microcentrifuge, Heraeus Thermo), freeze drier (Virtis TM mobile freeze-dryer, 
model 125L), magnetic stir bar (5 cm), ceramic mortar, Buchner funnel (funnel 
base 210 mm), desiccator, Whatman No. 1 paper filter, nylon syringe filters (25 
mm diameter, 0.45 µm pore size), micropipettes, HPLC filter unit (Millipore Cameo 
25 AS, DDA 02025So MSI: Micro separation Inc., USA), membrane filters 
(Durapore, 0.45 µm HV, Millipore), FTIR instrument fitted with UATR and 
controlled with Spectrum® software version 6.3.5.0176 (Perkin-Elmer 100, 
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Perkin-Elmer, USA), Fine Coat Ion Sputter (JFC-1100, JEOL, Tokyo, Japan), 
Auriga CrossBeam microscope (Zeiss, Germany), Zetasizer nano-series (Malvern 
instruments, Model Nano-ZS90, United Kingdom ), Zetasizer software (version 7.11, 
Malvern Instruments Ltd), rotator shaker, HR 73 halogen moisture analyser 
(Mettler Toledo, Model H73,United States of America), cuvette and folded capillary 
zeta cell. 
 
The HPLC system (Agilent, Model 1200 series, Chemetrics) used consisted of a 
vacuum degasser (Agilent 1200 series, Model G1322A, Germany), autosampler 
(Agilent 1200 series, Model G1329A, Germany), thermostatted column 
compartment (Agilent 1200 series, Model G1316A, Germany), a quaternary pump 
(Agilent 1200 series, Model G1311A, Germany), a diode array detector (DAD) 
(Agilent 1200 series, Model G1315B, Germany), a PC with Chemstation® software 
(Agilent, OpenLAB CDS Chemstation Edition LC and CE version A.01.04(033)) and a 
reverse phase column (Luna® 5 μm, C18, 250 x 4.60 mm, Phenomenex, United 
States of America). 
 
4.2.2 Chemicals 
The following chemicals and reagents were used: 
 
Acetonitrile and methanol (HPLC grade, Burdick & Jackson, United States of 
America), ethanol, sodium nitrate and aluminium chloride (Merck, Darmstadt, 
Germany), formic acid and sodium acetate (BDH Chemicals Ltd, England), 
hydrochloric acid 32% w/v (Kimix, USA), monobasic potassium phosphate, 
distilled water (prepared with Millipore filtration system 40/35), ethyl acetate 
(Saarchem, South Africa), sodium hydroxide, polymethylmethacrylate, acetone, 
dry ice, dichloromethane, tetrahydrofuran, triton X-100, polyvinyl alcohol, 
cholesterol, α-L phosphatidylcholine, 1-octanol and reference standard luteolin 
(Sigma Aldrich, Germany). All other materials and reagents were either of analytical 
grade or of the highest purity and used as received. 
 
4.2.3 Materials 
Dried A. afra leaves were purchased from local industrial herbal supplier Grassroot Group 
(Pty) Limited (UWC voucher number 6867, Groenvlei Farm, South Africa), placed in plastic 
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bags and stored in a temperature controlled laboratory room at 20oC in a dark place away 
from light. 
 
4.3 Methods 
4.3.1 Preparation and characterisation of A. afra freeze dried aqueous extract (FDAE) 
 
4.3.1.1 Preparation of freeze dried aqueous extract (FDAE) powder from Artemisia 
afra leaf material 
The aqueous extract was prepared by adding boiling distilled water to dried A. afra leaves in 
a ratio of 1:20 of mass (in grams) of dried leaves to volume (measured in millilitres) of 
distilled water (Mukinda et al., 2010). The mixture was boiled for 30 minutes, cooled at room 
temperature and then filtered under vacuum using a Buchner funnel with Whatman No. 1 
filter paper. The filtrate was transferred into a 250 ml round bottom flask, shell frozen and 
thereafter freeze-dried under vacuum (Virtis TM mobile freeze-dryer, model 125 L) for 48 
hours. The FDAE powders from the different batches were combined into a single final 
homogenous batch and weighed to determine the percentage yield. Finally, the FDAE powder 
was placed in stoppered amber glass bottles to protect it from light and stored at room 
temperature in a desiccator until used. 
 
4.3.1.2 Characterisation and evaluation of the Artemisia afra freeze dried aqueous 
extract powder 
 
4.3.1.2.1 Determination of organoleptic properties 
4.3.1.2.1.1 Colour 
To determine the colour of the FDAE, 0.2 g of the material was placed against a white 
background in diffuse daylight, viewed by eye and its colour described accordingly. 
 
4.3.1.2.1.2 Odour 
To determine the odour of the FDAE, 0.4 g of the material was placed in a 5 cm diameter 
watch glass, left for 15 minutes and thereafter the air above the sample was inhaled slowly 
and repeatedly. The strength of the odour was determined by classifying it as either non-
existent, weak, distinct or strong and the odour sensation described as either aromatic, fruity, 
musky, mouldy or rancid (WHO, 2011). 
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4.3.1.2.1.3 Taste 
For the taste determination, the FDAE of A. afra was dispersed in distilled water at a 
concentration of 0.01 g/ml, stirred and allowed to stand for 10 minutes before the researcher 
tasted 0.5 ml of the mixture by mouth. The taste was described in terms of none, sweet, sour 
or bitter. 
 
4.3.1.2.2 Determination of extractable matter and solubility 
The amount of extractable matter and degree of solubility of the FDAE in distilled water and 
buffers pH 1.2 and pH 6.8 were determined at room temperature. Accurately weighed 0.2 g 
of the FDAE in a glass-stoppered 10 ml test tube, added 5 ml of the solvent and mixed for 6 
hours, by hand shaking for 1 minute every 30 minutes. Then, the mixture was allowed to 
stand for a further 18 hours, before being rapidly filtered using a vacuum pump and a 
previously weighed Whatman No.1 filter paper (WHO, 2011). The filter paper containing the 
residue was then dried in an oven at 35 °C for 6 hours, placed in a desiccator for 30 minutes 
to equilibrate to room temperature and immediately thereafter weighed. 
To calculate the weight of the residue, the weight of the empty filter paper was subtracted 
from the combined weight of the dried filter paper with residue and the extractable matter, 
which also resembles solubility, determined using Equation 4.1 and expressed in terms of mg 
per gram of plant material.  
 
Extractable matter = Initial weight of plant material – weight of residue Eqn. 4.1 
    Weight of initial plant material 
 
In addition, the solubility was determined using the following equation (Eqn. 4.2): 
 
Solubility = Initial weight of plant material – weight of residue x 100  Eqn. 4.2 
   Volume of solvent 
 
Finally, the solubility of the material was described using the common descriptive phrases of 
solubility and the corresponding quantitative solubility ranges given in the BP 2013 (Table 
4.1) and expressed in terms of “parts”, which represented the number of millilitres (ml) of the 
solvent, in which 1 g of the solid was soluble. 
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Table 4.1: Common descriptive phrases of solubility and the corresponding quantitative 
solubility ranges (BP, 2013). 
 
Descriptive phrase Approximate quantities of solvent by 
volume for 1 part of solute by weight 
Very soluble Less than 1 part 
Freely soluble From 1 to 10 parts 
Soluble From 10 to 30 parts 
Sparingly soluble From 30 to 100 parts 
Slightly soluble From 100 to 1000 parts 
Very slightly soluble From 1000 to 10, 000 parts 
Practically insoluble More than 10, 000 parts 
 
4.3.1.2.3 Determination of moisture content of A. afra FDAE 
The moisture content of A. afra FDAE was determined using a gravimetric method which 
involved the determination of a loss in mass on drying (Souza, Bott & Oliveira, 2007). For 
this, an HR73 Halogen Moisture Analyser was used. Samples of a minimum of 0.1 g FDAE 
were evenly spread on the sample pan and inserted into the analyser. The moisture analyser 
automatically weighed and heated (105 °C) the sample and calculated the percentage loss on 
drying. The equations below illustrate how the moisture analyser determined the percentage 
moisture content. 
 
Moisture weight= Initial weight (Before drying) – Final weight (After drying) Eqn. 4.3   
 
Moisture content = Moisture weight   x 100     Eqn. 4.4 
   Initial weight 
 
4.3.1.2.4 Determination of the Total Flavonoid Content of A. afra FDAE 
The aluminium chloride colorimetric method (Barku et al., 2013), with minor modifications, 
was used to measure the flavonoid content of the FDAE. Briefly, an aqueous solution of the 
FDAE (0.25 ml, 1 mg/ml) was added to 1.25 ml of distilled water. Sodium nitrate solution 
(0.075 ml, 5% w/v) was then added to the mixture followed by incubation at room temperature 
for 5 minutes after which 0.15 ml of 10% w/v aluminium chloride was added. The mixture 
was allowed to stand for 6 minutes at room temperature before 0.5 ml of 1 M sodium 
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hydroxide was added and, finally, the mixture diluted with 0.275 ml distilled water. The 
absorbance of the reaction mixture was immediately measured at 350 nm with an HPLC 
Diode Array Detector. Quercetin was used as the standard and standard solutions of 12.5, 25, 
50, 80 and 100 µg/ml of quercetin in 80% methanol for the calibration curve. From the UV 
absorbance of the FDAE test sample, the flavonoid concentration (in terms of quercetin 
equivalents, QE) was determined from the calibration curve and the total flavonoid content 
(TFC) determined according to Equation 4.5 and expressed as mg QE/g dry weight (D.W.). 
 
TFC = QE x (V/M)       Eqn. 4.5 
 
where TFC is the total flavonoid content expressed in mg QE/g; QE is quercetin equivalent 
concentration (in mg/ml) of quercetin solution established from the calibration curve; V is the 
volume (in ml) of the extract solution and M is mass of the plant extract (in g). Three 
replicate samples were assayed and the TFC reported as average +/- standard deviation value. 
 
4.3.1.2.5 Development and validation of HPLC assay for luteolin 
In addition to its TFC, the A. afra FDAE was also characterised in terms of its luteolin 
content, the selected marker compound for the study, and for this an HPLC method was 
developed. The method developed (and eventually used) was based on previous gradient 
elution methods used by Nkengla (2014) and Tikiso (2015), which were simply modified to 
suit the current study. 
Briefly, separation of the marker compound was effected on a Phenomenex Luna® C-18 
column (250 x 4.6 mm, 5 µm) kept at temperature of 25oC and a mobile phase consisting of 
0.1% v/v formic acid aqueous solution (solvent A) and 0.1% 
v/v formic acid in acetonitrile 
(solvent D) used. Both solvents were filtered and degassed by membrane filtration prior to 
use. The elution gradient used was: 0-22 min 15% D; 22-27 min 100% D; 27-35 min 15% D; 
solvent flow rate 0.8 ml/min; the sample injection volume 20 μl and the luteolin peaks 
detected at 350 nm. 
 
To validate the assay, the linear concentration range, assay specificity and precision, and 
limits of detection and quantification were determined. For this, a stock solution of luteolin, 
165 µg/ml of 75% methanol, was prepared and from this standard solutions in concentration 
range 2.6 to 82.5 µg/ml 75% methanol were used to plot the calibration curve. 
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The linearity of the calibration curve for the reference standards was assessed in triplicate 
over a six sample concentration range, the calibration curves constructed as plots of peak area 
against concentration (ICH, 2005), subjected to linear regression and the correlation 
coefficient (R2) determined using GraphPad Prism 6. 
 
The detection and quantification limits (i.e. LOD and LOQ, respectively) were determined 
using the standard deviation of the response and the slope of the curve, and the following 
equations (ICH, 2005); 
 
LOD = 3.3 σ       Eqn. 4.6 
S 
 
LOQ = 10 σ       Eqn. 4.7 
S 
 
where σ is the standard deviation of y-intercepts of regression lines and S is the slope of the 
calibration curve.  
 
To determine the specificity of the assay, firstly, 150 µl of luteolin standard (165 µg/ml) was 
spiked with 150 µl of components of the phytosome matrix. The latter matrix was prepared 
by lysing extract free (unloaded) phytosomes with Triton X-100. The sample was prepared in 
triplicate and analysed on the HPLC system. Using the Chemstation® peak analysis function, 
peak purity tests were used to show that the luteolin chromatographic peak was not 
attributable to more than one compound. Also, the chromatograms were compared to identify 
any interference between the blank phytosome matrix with luteolin. Secondly, to determine 
the specificity of the assay for luteolin in the plant extract, chromatograms of standard 
luteolin sample (165 µg/ml) and FDAE solution were compared for peak retention time and 
the peak in the chromatogram of the FDAE solution subjected to peak purity analysis using 
the Chemstation® software. 
 
Lastly, to determine the precision of the assay, 3 replicates of the low, medium and high 
concentration standard solutions were assayed three times a day, for three consecutive days 
and on each occasion the mean peak area, standard deviation and % relative standard 
deviation (RSD) calculated. 
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4.3.1.2.6 Quantification of luteolin content in Artemisia afra FDAE 
The afore-mentioned validated assay was subsequently used to determine the levels of 
luteolin, the marker compound, in the A. afra FDAE. Specifically, the FDAE was evaluated 
for total, free and conjugated luteolin. 
 
Briefly, a 3 ml solution of 15 mg/ml (50% methanol) of the FDAE was prepared, filtered 
using a 0.45 µm syringe filter and the filtrate divided into two 1 ml samples for analysis of 
unhydrolysed (free) luteolin and hydrolysed (total) luteolin. For the unhydrolysed luteolin, 20 
µl of the sample was injected onto the HPLC system for analysis. For the assay of the 
hydrolysed luteolin however, 0.5 ml of 2 N hydrochloric acid and 0.5 ml of methanol were 
added to the 1 ml FDAE sample, the mixture vortexed for 30 seconds, left to ‘hydrolyse’ in a 
water bath at 80°C for 40 minutes, thereafter allowed to cool under room temperature and 
then, finally, centrifuged for 10 minutes at 5 000 rpm. The supernatant (20 µl) was then 
injected onto the HPLC system for analysis. 
 
To identify luteolin in the plant samples, the UV spectra and retention times of the peaks 
obtained from the chromatograms of the plant samples were compared to that obtained with 
the pure luteolin standard solutions. Finally, the area of the luteolin peak was noted and the 
levels of free or total luteolin in each sample determined from the standard curve regression 
equation. The level of conjugated luteolin was determined by subtracting the free 
(unhydrolysed) luteolin level from the total (hydrolysed) luteolin level. Three replicates of 
each preparation were assayed. 
 
4.3.1.2.7 Determination of oil/water partition coefficient (log P) of the FDAE 
The partition coefficient was determined using the shake flask method (Berthod & Carda-
Broch, 2004) with two different solvent systems. The first solvent system consisted of 1-
octanol and 0.1 N hydrochloric acid (pH 1.2), and was designed to simulate gastric conditions 
while the second solvent system was a combination of 1-octanol and phosphate buffer (pH 
6.8) and designed to simulate intestinal conditions. 
 
Equal volumes of each solvent system [i.e. 1-octanol (10 ml) and phosphate buffer (10 ml), or 
1-octanol (10ml) and 0.1 N hydrochloric acid (10 ml)] were equilibrated in a pear-shaped 
separatory funnel by shaking for 24 hours in order to co-saturate the two phases and then left 
to separate for 12 hours before being stored at room temperature for further use. 
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To determine the log P, 75 mg of FDAE was dissolved in 3 ml of the pre-saturated aqueous 
solvent. To this solution, 3 ml of the pre-saturated 1-octanol was added, the mixture shaken 
continuously for 24 hours, then centrifuged at 5 000 rpm for 10 minutes, the two phases 
separated by means of a pipette and finally, the samples thereof transferred to HPLC sample 
vials and each injected (20 µl) into the HPLC system to determine the concentrations of 
luteolin. The experiment was done in triplicate and the ratio of the luteolin concentration in 
the 1-octanol phase to the luteolin concentration in the respective aqueous phase was used to 
calculate the log P value using Equation 4.8 (Van Zyl, 2012). 
 
Log P =   log Concentration of luteolin in organic phase (1-octanol)  Eqn. 4.8 
          Concentration of luteolin in aqueous phase 
 
 
4.3.2 Preparation and characterisation of A. afra phytosomes 
 
4.3.2.1 Preparation of the A. afra phytosomes  
The phytosomes were prepared using the aqueous mechanical dispersion solvent evaporation 
method of Sikarwar, Sharma et al. (2008), with minor modifications. Based on a factorial 
design, varying masses (100 and 200 mg) of phosphatidylcholine (PC) and a fixed mass of 
the FDAE (100 mg) were weighed on the analytical balance (Ohaus, PA413) and dissolved in 
20 ml of organic solvent (tetrahydrofuran or dichloromethane) and 20 ml of distilled water, 
respectively. Using 0.45 µm nylon membrane syringe filters the mixtures were separately 
filtered, into a 50 ml glass beaker (FDAE) and a 100 ml Erlenmeyer flask (PC). 
 
A 5 cm magnetic stirring bar was then placed in the flask containing the PC solution and, 
with the aid of a clamp, the flask secured onto the magnetic stirrer as shown below (Figure 
4.1). Thereafter, the FDAE solution was added drop-wise over 5 minutes, via a 20 ml syringe, 
into the PC solution which was continuously stirred (800 – 1000 rpm) at room temperature. 
The mixture was stirred for a total of 60 minutes and immediately after mixing, it was 
transferred to a 100 ml round bottom flask, rota-vaporated under vacuum at 40oC for 30 
minutes (to remove any residual organic solvent), vortexed for 3 minutes, sonicated in an 
ultrasonic bath for 30 minutes before filling three Eppendorf tubes (T1, T2 and T3) with 1 ml 
of the mixture for analysis of complex formation efficiency and further characterisation. 
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Figure 4.1: Set up of the equipment for the preparation of A. afra phytosomes 
 
4.3.2.2 Experimental design for determination of factors affecting complex formation 
efficiency. 
To determine the effect of various parameters on the efficiency of the complex formation 
(CFE) between the phospholipids and phytoconstituents in the A. afra FDAE phytosomes, a 
23 full factorial experimental design (Bhalerao & Raje Harshal, 2003; Joshi et al., 2012; Shah 
& Pathak, 2010) was implemented. For this analysis Design-Expert® version 8 software was 
used. 
 
Three independent variables, namely, mass ratio of FDAE to phospholipids (X1), stirring 
speed (X2) and type of organic solvent (X3) were taken at two levels: low and high, which 
were represented by transform (coded) values of −1 and +1, respectively. Values used for 
these selected variables are shown in Table 4.2. 
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Table 4.2: Key to the 23 factorial design 
Factor  Parameter      Levels 
       Low (-1)  High (+1) 
X1  Mass ratio of FDAE: PC  1:1   1:2 
X2  Stirring speed    800 rpm  1000 rpm 
X3  Organic solvent   Dichloromethane Tetrahydrofuran 
 
Sixteen batches (eight formulations duplicated) were prepared according to the experimental 
design (shown in Table 4.3) and were evaluated for complex formation efficiency (CFE), Y, 
(dependent variable). Fitting a multiple linear regression model to the factorial design gave a 
predictor equation which was a first order polynomial, having the form, 
 
Y = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3  Eqn. 4.9 
 
where, Y was the dependent variable; b0, an intercept representing the arithmetic mean 
response of all quantitative outcomes of sixteen runs, and bi the estimated coefficient for the 
factor Xi.  
 
In order to ensure a good model, tests for significance of the regression model, significance 
on individual model coefficients and for lack-of-fit were performed using analysis of variance 
(ANOVA) and regression coefficients (Vali et al., 2008). The model was then used to 
identify the parameters that significantly affected CFE, with level of significance set at p < 
0.05. 
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Table 4.3: Coded factorial design set up 
Formulation   X1   X2   X3  
    (mass ratio)  (stirring speed) (organic solvent)  
F1    +1   - 1   - 1  
  
F2    +1   +1   - 1  
  
F3    - 1   - 1   - 1  
  
F4    - 1   +1   - 1  
  
F5    - 1   +1   +1  
  
F6    +1   - 1   +1  
  
F7    - 1   - 1   +1  
  
F8    +1   +1   +1  
  
F9    +1   - 1   - 1  
  
F10    +1   +1   - 1  
  
F11    - 1   - 1   - 1  
  
F12    - 1   +1   - 1  
  
F13    - 1   +1   +1  
  
F14    +1   - 1   +1  
  
F15    - 1   - 1   +1  
  
F16    +1   +1   +1  
  
 
 
4.3.2.3 Characterisation of the A. afra phytosomes 
 
4.3.2.3.1 Determination of phospholipid-phytoconstituent complex formation 
efficiency (CFE) 
The efficiency of complex formation between the A. afra FDAE phytoconstituents and 
phosphatidylcholine was determined using luteolin as marker compound and Equation 4.10. 
Briefly, to determine the uncomplexed (free) luteolin content, sample T1 was centrifuged at 
10 000 rpm for 20 minutes after which 0.5 ml of the supernatant was carefully withdrawn by 
pipette, without disrupting the pellet, and transferred to an HPLC vial for analysis on the 
HPLC system (Agilent 1200 series). To determine the total (i.e. complexed plus 
uncomplexed) luteolin content, Triton X-100 (0.075 ml; to lyse the phytosomes) was added 
to the T2 sample, the mixture vortexed for 5 minutes, centrifuged at 6 000 rpm for 10 minutes 
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(Baxter, 13 Microcentrifuge, Heraeus Thermo) and, finally, 0.5 ml of the supernatant solution 
transferred to an HPLC vial for luteolin content analysis on the HPLC system. The complex 
formation efficiency was then calculated using Equation 4.10. 
 
Complex formation efficiency % = Total luteolin – Free luteolin     x 100 Eqn. 4.10 
                                                                      Total luteolin 
 
4.3.2.3.2 Determination of particle size and distribution and, colloidal stability 
To determine the particle size, particle size distribution and colloidal stability, the T3 sample 
was centrifuged at 10 000 rpm for 20 minutes (Baxter, 13 Microcentrifuge, Heraeus Thermo), 
the supernatant removed, 1 ml of distilled water added, the mixture vortexed for 1 minute to 
re-disperse the pellet and then centrifuged at 10 000 rpm for 20 minutes. This washing of the 
pellet was repeated twice. Thereafter the pellet was re-dispersed in distilled water by 
vortexing for 3 minutes, sonicated for 10 minutes in an ultrasonic bath and finally aliquots of 
this suspension were pipetted into a cuvette and folded capillary zeta cell, for analysis of 
particle size and distribution, and zeta potential, respectively, on the Zetasizer (Malvern 
instruments, Model Nano-ZS90). The particle size and distribution analyses were conducted 
at 25oC and the zeta potential measurement at pH 6.43 and 25oC. Attenuator setting and 
measurement duration were set to automatic and number of runs and measurement angle 
were set at 3 runs per sample and 90o, respectively. 
 
4.3.2.3.3 Fourier Transformation Infrared (FTIR) spectra 
Infra-Red spectra of the phytosomes, phospholipids, FDAE and a physical mixture of the 
FDAE and phospholipids were obtained using a Perkin- Elmer 100 FTIR instrument fitted 
with UATR and controlled with Spectrum® software version 6.3.5.0176. Samples in powder 
form were analysed over the wavelength range 400 - 4000 cm-1 and the percentage 
transmittance recorded against frequency. 
 
4.3.2.3.4 Determination of the phytosome particle surface morphology 
The surface morphology of the phytosome particles was determined using the scanning 
electron microscopy technique. First, the phytosomes were coated with gold in a Fine Coat 
Ion Sputter JFC-1100. Then the stub with the coated phytosomes was placed in the Zeiss 
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AURIGA® CrossBeam scanning electron microscope and surface morphology viewed and 
photographed. 
 
4.3.2.3.5 Determination of the apparent solubility of A. afra phytosomes and FDAE 
To determine the apparent solubility of luteolin in the preparations, an excess of the 
phytosomes or FDAE was added to 5 ml of water or n-octanol in sealed glass containers at 
room temperature (Khan et al., 2014). The liquid was agitated for 24 hours on rotator shaker, 
centrifuged for 20 minutes at 4 000 rpm, the supernatant (0.5 ml) filtered through 0.45 µm 
nylon membrane filter, transferred into an HPLC sample vial for analysis on the HPLC to 
quantify amount of luteolin present and finally, the concentration of luteolin determined for 
each preparation in each solvent. All experiments were conducted in triplicate and average 
values compared using the Student t-test with level of significance set at p < 0.05. 
 
4.4 Results and discussion 
 
4.4.1 Preparation and characteristics of A. afra FDAE 
4.4.1.1 Yield of freeze-dried aqueous extract  
The aqueous extract was prepared in a way that closely mimicked the method traditional 
herbal practitioners use to extract their plant medicines. This was done to minimise variations 
in the phytochemical content of the FDAE compared to the traditional decoction. In the 
present study a moderate yield of 26.2% (Table 4.4 and Appendix 1) was obtained. This was 
however similar to yields obtained in other A. afra studies, viz. the 21.8, 21.96 and 28.4% by 
Nkengla (2014), Dube (2005) and Komperlla (2004), respectively. This may be attributed to 
similar extraction methods used. 
 
Table 4.4: Characteristics of A. afra FDAE 
Characteristic Result 
Yield (%) 26.16 ± 2.90 
Moisture content (%) 2.47 ± 0.15 
Total flavonoid content (mg QE/g) 34.1 ± 6.4 
Luteolin content Un-hydrolysed (µg/mg) 0.45 ± 0.01 
Hydrolysed (µg/mg) 1.92 
Conjugated (%) 76.6 
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4.4.1.2 Organoleptic properties 
Usually, an examination of organoleptic characteristics is the first step towards establishing 
the identity and the degree of purity of plant materials. If, in terms of colour, consistency, 
odour or taste, a plant material sample is found to be significantly different from the set 
specifications, it is considered as not fulfilling the requirements. The results obtained for the 
FDAE of A. afra are summarized in Table 4.5. 
 
Table 4.5: Organoleptic properties of A. afra FDAE 
Organoleptic property Description 
Colour and appearance 
 
Odour 
Taste 
Pale brown coloured powder which turns to a dark brown 
deliquescent gum on prolonged exposure to the air  
Aromatic 
Extremely bitter 
 
The Artemisia afra had a characteristic aromatic odour which emanated from its essential 
oils. Compounds such as α- and β-Thujone (52.1 - 39.8%), camphor (14.4 - 8.2%), 1, 8-
cineole (21.8–13.1%) and borneol (7.8 - 2.7%) are known to be the major components 
responsible for the characteristic flavour of the species (Asekun, Grierson & Afolayan, 2007).  
 
Colour can be used as a means of identifying a particular substance and several 
Pharmacopoeias include the colour of the substance as part of the substances monograph. The 
FDAE produced in the current study was light brown in colour but turned dark brown on 
extended exposure to air (Figure 4.2). The change in colour and appearance was most likely 
due to the hygroscopic nature of the FDAE as was also reported in several other studies 
(Komperlla, 2004; Dube, 2006; Nkengla, 2014).  
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Figure 4.2: Physical appearance of A. afra FDAE 
 
Finally, the FDAE had an extremely bitter taste. Bitterness is usually quantified with a so-
called bitterness value and determined by comparison with quinine hydrochloride, for which 
the bitterness value is set at 200 000. Olivier and Van Wyk (2013) recorded a bitterness value 
of 26 393 ± 29 759 for Artemisia afra, to some extent confirming the bitter taste obtained in 
the present study (Olivier & van Wyk, 2013).  Several other studies have also obtained a 
similar qualitative severity of bitterness associated with this species (Dube, 2006; Nkengla, 
2014; Wagner & Wiesenauer, 2003). For instance, Dube (2006) recorded a bitterness of 600 
000, triple that of the quinine standard. The difference in the bitterness values obtained by 
Olivier and Van Wyk (2013) and Dube (2006), and, the large standard deviation documented 
by former authors are however evidence that this test, because it is based on an individuals’ 
sensory functions, is generally prone to large errors. Nevertheless, the qualitative description 
of the taste was consistent in all previous studies and the present one. 
 
4.4.1.3 Extractable matter and solubility 
This characteristic gives an indication of the amount of active constituents extracted with 
solvents from a given herbal material.  It is generally employed for materials for which no 
suitable chemical or biological assay exists as yet (WHO, 2011). 
 
The results (Appendix 2) obtained for the A. afra FDAE in the present study are summarised 
in Table 4.6. 
 
 
 
 
http://etd.uwc.ac.za/
56 
 
Table 4.6: Extractable matter and solubility of A. afra FDAE in various solvents 
Solvent      Extractable matter*   Solubility*                  Description 
       (mg/g)      (Parts)      mg/ml       
 
Water          888 ± 62       27.9 ± 1.4      35.9 ±1.8          soluble 
pH 1.2 buffer         847 ± 2.6       27.1 ± 0.1      36.9 ± 0.1          soluble 
Phosphate buffer (pH6.8)  983 ± 3.2                  24.8 ± 0.3      40.4 ± 0.2          soluble  
*n = 2 
According to the common descriptive phrase of the BP 2013, the A. afra FDAE was soluble 
in all the solvents investigated. This was as predicted, given that the extract was derived by 
aqueous extraction. In contrast to the finding of this study, Nkengla (2014) and Komperlla 
(2004) reported their extracts as being sparingly soluble and requiring 38.7 and 40 ml of 
water, respectively, to dissolve 1 g of extract. The solubility and amount of extractable matter 
in the buffer systems was of interest as the buffer conditions used were similar to those found 
in the gastrointestinal tract and the results would indicate the extent of availability of extract 
for absorption in the stomach (pH 1.2) and small intestines (pH 6.8). Of note, the solubility 
was not pH dependant and the good solubility of A. afra actives ingredients in the present 
study was thus a good finding. 
 
4.4.1.4 Moisture content 
Moisture content is one of the most important factors influencing quality and storability of 
plant materials. Pharmacopoeias generally recommend the use of the oven drying method to 
determine the moisture content of plant materials but in this study a halogen moisture 
analyser was used because it was quick and efficient. The moisture content of the FDAE was 
found to be 2.47 ± 0.15% (Table 4.4 and Appendix 3). This low moisture level was desirable 
because it discourages hydrolysis and microbial growth and thereby ensures preservation of 
the extract. Indeed, residual moisture levels > 1 to 5% are generally regarded as acceptable 
for solid oral dosage forms (FDA, 1990).  In addition, the result obtained in this study was 
also lower than that obtained by other authors, e.g. 8.62% by (Dube, 2006) and 10.68% by 
(Nkengla, 2014).  
 
Overall, the low moisture content result obtained may have been attributed to the shell 
freezing technique, which ensured quick and uniform drying of the sample, but, 
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unfortunately, this reason cannot be asserted as the aforementioned authors did not detail 
their respective freezing techniques. In addition, the low moisture may also be attributed the 
analysis method used, as the halogen moisture analyser, minimises human error unlike the 
oven drying method. 
 
4.4.1.5 Total Flavonoid Content (TFC) of the FDAE 
The TFC of the extract was determined using the aluminium chloride colorimetric method, 
with quercetin (QE) used as the standard and a calibration curve of absorbance peak area 
versus quercetin concentration constructed (Figure 4.3). Linearity (R2 = 0.999) was 
established within the concentration range of 12.5 – 100 µg/ml. The flavonoid content was 
expressed in terms of quercetin equivalent (mg of QE) per g of extract, and the results 
obtained are shown in Table 4.4.  
 
Figure 4.3: Standard curve of quercetin concentration versus absorbance area at 350 nm used 
for the quantification of the total flavonoid content 
 
The TFC of the A. afra FDAE was found to be 34.1 ± 6.4 mg QE/g, a level fairly similar to 
that found in other species; e.g. 32.317 ± 0.629 mg QE/g  in Pseuderanthemum palatiferum 
(Nees) radlk, (Nguyen & Eun, 2011; Zhishen, Mengcheng & Jianming, 1999) and 26.6 mg 
QE/g in Morus alba L., (Zhishen, Mengcheng & Jianming, 1999). Nkengla (2014) also 
determined the TFC of a FDAE of A. afra but used a different method from the one used in 
the present study and obtained a level of 24.5 mg LUT/g (Nkengla, 2014). Although the latter 
finding is reasonably similar to that found in the present study, the two results can however 
not be directly compared because of differences in the method used.  
 
Overall, the FDAE had a reasonably high TFC, which was expected, as the genus, 
Artemisia L. has been documented to contain over 160 flavonoids (Avula et al., 2009) and the 
http://etd.uwc.ac.za/
58 
 
presence of high and quantifiable flavonoid content, therefore also makes the TFC a potential 
quality control parameter for A. afra preparations. 
 
4.4.1.6 Validation of HPLC assay for luteolin 
A reverse phase HPLC method was developed for the quantification of luteolin, the selected 
marker compound for the study. The assay developed showed luteolin peaks with good 
symmetry, retention time of 28.60 ± 0.11 minutes (Figure 4.4) and UV spectrum (Figure 4.4 
inset) showing maximal absorption around 350 nm as expected of flavonoids.  
 
Figure 4.4: Typical HPLC chromatogram for the luteolin reference standard at 350 nm. Inset: 
UV/Vis spectrum for the reference compound at ~28.6 min 
 
The results of the validation are summarized in Table 4.7. The six-point peak area versus 
concentration of luteolin standard curve was linear in the range of 2.58 - 82.5 μg/ml (i.e. 
51.6 – 1650 ng of luteolin on column) (Figure 4.5), described by the equation 
y = 90.01x + 13.86 (where y = peak area, x = luteolin concentration in μg/ml) and had a 
regression correlation coefficient, R2 value of 0.999. 
 
Figure 4.5: Calibration curve of mean peak area against the concentration of replicate samples 
of luteolin at 350 nm 
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The average intra-day and inter-day precision was 0.986 ± 0.728% and 1.202 ± 0.672%, 
respectively. The assay method was therefore deemed as precise since the %RSD was less 
than 2% (FDA, 2000). The limits of detection and quantification were 0.03 μg/ml (0.61 ng on 
column) and 0.09 μg/ml (1.84 ng on column), respectively.  
 
Table 4.7: Summary of luteolin HPLC assay validation results 
Validation parameter Acceptability criteria Result 
Linearity R2 ≥ 0.997 (ICH, 2005) 0.999 
Precision  Inter-day  %RSD ≤ 2% (FDA, 2000) 0.986 ± 0.728% 
1.202 ± 0.672% Intra-day 
LOD - 0.03 μg/ml 
LOQ - 0.09 μg/ml 
Specificity Peak purity test (ICH, 2005) No interference 
Accuracy Infered if linearity, precision and 
specificity are established (ICH, 2005) 
Infered 
 
The specificity of the assay was confirmed by the peak purity test (UV spectra insert A in 
Figure 4.6) which showed that the luteolin chromatographic peak was only attributable to one 
compound and that there was therefore no interference with the elution of luteolin. In 
addition, the chromatograms showed that there was no co-elution with any component of the 
blank phytosome matrix at the luteolin retention time. 
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Figure 4.6: HPLC chromatogram for spiked (top) and blank phytosome matrix (lower). Inset A 
and B represent the peak purity test and UV spectrum at 350 nm 
 
Collectively, the validation results showed acceptable validity and reproducibility and hence 
the HPLC assay for luteolin was deemed suitable for use. 
 
4.4.1.7 Identification and quantification of luteolin in A. afra FDAE 
Using the aforementioned validated HPLC assay (section 4.4.1.6), levels of luteolin in the 
FDAE were quantified. Representative chromatograms of un-hydrolysed and hydrolysed 
samples of A. afra FDAE are shown in Figures 4.7 and 4.8, respectively, and the luteolin 
levels in the FDAE are depicted in Tables 4.4 and 4.8. 
 
Figure 4.7: Representative HPLC chromatogram of unhydrolysed FDAE of A. afra. The 
retention time of luteolin at 28.627 minutes 
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Figure 4.8: Representative HPLC chromatogram of hydrolysed FDAE of A. afra. The retention 
time of luteolin at 28.585 minutes 
 
The chromatograms of the hydrolysed and un-hydrolysed A. afra samples showed peaks of 
several other compounds, of which most had a UV/Vis spectrum similar to that of flavonoids. 
These peaks therefore most likely indicated the presence of other flavonoids and or 
glycosides of luteolin. However, the luteolin peak (retention time 28.5± 0.255 min) was 
confirmed by spiking samples and by UV spectral analysis done using the diode array 
detector and HPLC Chemstation® software. 
 
Overall, the FDAE contained 0.45 ± 0.01, 1.92 ± 0.01 and 1.47 ± 0.01 µg/mg of free, total 
and conjugated luteolin (Table 4.8). Most (76.6%) of the luteolin was in the conjugated form 
as expected. Normally, the majority of flavonoids present in the leafy parts of plants are in 
the form of O- and C- glycosides (e.g. glucosides, rutinosides, glucopyranoside) and this was 
confirmed by the results of the present study where after acid hydrolysis of the FDAE, the 
luteolin levels quadrupled in comparison to the unhydrolysed sample. The conjugates were 
generally unstable and could be easily hydrolysed to the aglycone form, and this 
characteristic can thus be potentially also used as a quality control marker of stability, i.e. if 
the unhydrolysed extract showed an increased level of aglycone luteolin concentration then it 
may be an indication of degradation of the plant material. 
 
Table 4.8: Luteolin levels in FDAE of A. afra 
Luteolin content Unhydrolysed (µg/mg) 0.45 ± 0.01 
Hydrolysed (µg/mg) 1.92 ± 0.01 
Conjugated (%) 76.6 
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Other authors have reported varying concentrations of luteolin in A. afra FDAEs. For 
instance, Nkengla (2014) obtained 0.185 ± 0.24 and 0.235 ± 0.026 µg/mg, while, in contrast, 
Dube (2006) had higher levels, 7.0880 ± 0.4751 and 13.870 ± 1.2460 µg/mg of free and total 
luteolin, respectively. These variations in phytochemical concentrations are quite common 
and pose major challenges in the standardisation and quality control of herbal products. The 
variations mainly arise from differences in season and geographical location of harvest 
(Asekun, Grierson & Afolayan, 2007; Viljoen et al., 2006) and therefore should be factored 
in when standardising herbal products. 
 
All in all, luteolin was successfully identified and quantified by the validated HPLC assay 
and of note; the FDAE contained significantly more conjugated luteolin than the aglycone 
form. 
 
4.4.1.8 Oil/water partition coefficient (log P) of the FDAE 
The octanol–water partition coefficient is the accepted physicochemical property for 
measuring the lipophilicity of substances (Sangster, 1997) and is also used to predict the 
potential absorption of substances. The log P values obtained for the FDAE in the present 
study are given in Table 4.9 and showed that, in terms of both luteolin and TFC, the FDAE 
was more lipophilic under gastric (pH 1.2) than intestinal (pH 6.8) conditions. 
 
Table 4.9: Oil/water partition coefficient (log P) values of FDAE in pH 1.2 and pH 6.8 
 Partition coefficient 
pH 1.2 pH 6.8 
Luteolin 1.52 ± 0.004 0.44 ± 0.004 
Total flavonoid content -0.35 ± 0.06 -1.10 
 
Under gastric and small intestinal conditions, luteolin was more lipophilic than the total 
flavonoids. Despite the differences in lipophilicity under different conditions, all the log P 
values indicated that the phytoconstituents would be poorly absorbed (i.e. log P < 2) under 
both pH conditions. A log P value of between 3 to 4.6 is generally predictive of good 
http://etd.uwc.ac.za/
63 
 
absorption of the compound (Leeson & Springthorpe, 2007), while values less than 2 are 
reflective of hydrophilic compounds which are poorly absorbed. 
 
There are advantages and disadvantages associated with the use of luteolin and TFC as 
marker compounds in the determination of log P values. The use of luteolin is more 
representative of the aglycones (e.g. for quercetin, log P = 1.5; apigenin, log P = 1.7; 
genkwanin, log P = 2.1) (Pubchem, 2016) which are known to be more lipophilic than the 
glycosides (e.g. luteolin 7-glucoside, log P = 0.5) (Pubchem, 2016). As shown by the 
previous results in  section 4.4.1.7, the FDAE contained mostly flavonoid glycosides (76%) 
which are known to be hydrophilic (Evans, 2009), hence the aglycone log P value is not an 
accurate representation of the measure of lipophilicity of the whole extract. On the contrary, 
TFC depicts a more holistic measure of lipophilicity of the FDAE as it incorporates all 
flavonoids, which are known to be responsible for the extracts’ pharmacological action. The 
present study therefore portrays one of the disadvantages of using the aglycone marker 
compound for quality control purposes for an extract that contains numerous 
phytoconstituents. 
 
All summed up, as expected, the FDAE proved to be hydrophilic and therefore had a high 
potential to be poorly absorbed as evidenced by the low log P values.  
 
4.4.2 Preparation and characteristics of A. afra phytosomes 
Artemisia afra phytosomes were prepared using an aqueous based solvent evaporation 
mechanical dispersion method. This method is seldom used since the solvent evaporation and 
reflux techniques (Arora, Sharma & Kaur, 2013; Das & Kalita, 2014; Habbu et al., 2013; 
Khan et al., 2014; Mali et al., 2014; Yue et al., 2010) are generally preferred. These latter 
methods are applicable where the extract is soluble in an organic solvent. In this study, 
preliminary solubility studies revealed that the FDAE of A. afra was insoluble in 
dichloromethane, tetrahydrofuran, methanol, ethanol and diethyl ether, which therefore 
rendered the commonly used preparation methods unsuitable for preparation of the A. afra 
phytosomes. In addition, from a pharmaceutical production perspective, the aqueous based 
mechanical dispersion method minimises the amount of organic solvents used (which may be 
cumbersome to remove) and would be rapid and amenable to scale up procedures due to its 
simplicity. 
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In the preparation of the phytosomes, mass ratios of FDAE to phospholipids were used 
instead of the molar ratios due to the complexity of the phytoconstituents of the extract which 
are difficult to quantify in terms of molarity. In addition, the phospholipids contained ≥ 40% 
phosphatidylcholine; therefore, any stoichiometric molar ratio used would have been 
inaccurate. 
 
All in all, the preparation method was simple to use and presented no major challenges 
throughout all the preparation steps. 
 
4.4.2.1 Complex formation efficiency (CFE) 
To successfully develop a phytosomal drug delivery system, complex formation 
(encapsulation) efficiency is key as it represents the efficiency and acceptability of the 
preparation method followed (Khan et al., 2014). In this study the CFE was determined using 
an indirect method that took into account losses of excipients that incurred during the 
preparation of the phytosomes. The CFE results obtained are given in Table 4.10 and the 
sixteen batches showed a wide variation, from 21.2 to 68.7%, in CFE. The variation was 
generally similar to the 38.8 to 75.3% that Khan et al (2014) obtained in the preparation of 
luteolin phospholipid complexes. This therefore confirmed the suitability of the preparation 
technique. 
 
Table 4.10: Complex formation efficiency of sixteen phytosome formulations 
Batch  X1   X2   X3           Y  
code  (mass ratio)  (stirring speed) (Organic solvent) (CFE %) 
F1  +1   - 1   - 1   68.7 
F2  +1   +1   - 1   56.8 
F3  - 1   - 1   - 1   43.2 
F4  - 1   +1   - 1   43.8 
F5  - 1   +1   +1   41.0 
F6  +1   - 1   +1   56.0 
F7  - 1   - 1   +1   51.3 
F8  +1   +1   +1   38.6 
F9  +1   - 1   - 1   51.2 
F10  +1   +1   - 1   51.1 
F11  - 1   - 1   - 1   43.0 
F12  - 1   +1   - 1   33.2 
F13  - 1   +1   +1   21.2 
F14  +1   - 1   +1   57.1 
F15  - 1   - 1   +1   42.2 
F16  +1   +1   +1   37.9 
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Based on the aforementioned findings, the experimental variables that gave the highest CFE 
i.e. dichloromethane, 800 rpm and ratio of 1:2, were used to prepare another batch of 
phytosomes which was then lyophilised to produce the phytosomes in solid form. These 
lyophilised phytosomes were pale cream-yellow in colour, sticky non-free flowing powders 
(Figure 4.9). These characteristics were similar to those obtained by Das (2014) in the 
preparation of rutin phytosomes. 
 
 
Figure 4.9: Physical appearance of A. afra phospholipid complex  
 
The poor flow properties of the phytosomes were expected to pose a major challenge when 
encapsulating them for dissolution studies. Ideally, reformulation by addition of other 
excipients such as silicone dioxide and magnesium stearate was required so as to counteract 
the sticky nature of the phytosomes and thereby improve its flow properties. 
 
Suitability of phytosomes as potential drug carriers of the phytoconstituents of the FDAE was 
partly dependent upon the ability of PC to complex with most of the phytoconstituents. As 
previously stated, luteolin was the marker compound selected for the determination of the 
complex formation efficiency. However, luteolin was just one of the phytoconstituents 
present in the FDAE and it was therefore also necessary to qualitatively assess the complex 
formation in terms of the numerous other constituents. The chromatograms illustrated in 
Figure 4.10, show peaks representing phytoconstituents complexed to the PC. From visual 
comparison of chromatograms of the unhydrolysed FDAE (Figure 4.7) and unhydrolysed 
phytoconstituents present in the phytosome (Figure 4.10A), it can be noted that the 
unhydrolysed FDAE had about 29 compounds while the unhydrolysed phytosomes had 
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approximately 21 compounds. From this comparison it was evident that most of the 
phytoconstituents of the FDAE interacted with the PC to form the phytosome complex. 
 
 
 
Figure 4.10: Representative chromatograms of unhydrolysed (A) and hydrolysed (B) 
phytoconstituents present in the phytosome complex at 350 nm. Luteolin 
detectable at ≈ 28.5 minutes 
 
Interestingly, the chromatograms of the hydrolysed phytosome phytoconstituents showed no 
increase in the luteolin peak area, implying that complexing between PC and luteolin 
conjugates was either very low or non-existent. However, comparison of the phytosome 
chromatograms (Figure 4.10 A and B) revealed emergence of new peaks e.g. at Rt 
13.085 (iii), 16.830 (iv), 24.402 (v) and 26.449 (vi) minutes (Figure 4.10B) in the hydrolysed 
phytosome chromatogram and disappearance of peaks e.g. 17.528 (i) and 18.764 (ii) minutes 
(Figure 4.10A), previously present in unhydrolysed phytosome chromatogram. This may be 
evidence of the presence of conjugates (e.g. glycosides) which are acid hydrolysed (resulting 
in the disappearance of peaks or decrease in peak areas) to the aglycone form which may 
result in either emergence of a new peak or increase in existing peak area, thus confirming 
complexation of PC and the conjugates. In order to identify the compounds corresponding to 
the disappeared peaks, the UV spectra were analysed and the results obtained are shown 
below. 
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Figure 4.11: UV spectrum of peak at 17.528 minutes measured at 350 nm 
 
 
Figure 4.12: UV spectrum of peak at 18.764 minutes measured at 350 nm 
 
Both spectra strongly suggested that the compounds were flavonoid glycosides (maximum 
absorbance at ≈ 350 nm) due to the disappearance of the peaks upon acid hydrolysis. 
All in all, the phytosomes proved to be suitable drug carriers for at least the flavonoid 
phytoconstituents of A. afra FDAE as most of the phytoconstituents complexed with the 
phospholipids. 
 
4.4.2.2 Experimental design 
A full 23 factorial design incorporating one process (stirring speed) and two formulation 
variables (i.e. organic solvent and FDAE: PC mass ratio) taken at two levels, was used to 
design experimental batches to investigate the factors that affected CFE during the 
preparation of A. afra phytosomes. Selection of the factors (variables) and levels that could 
affect CFE were based on literature reports where varying molar ratios of drug to PC and 
different types of organic solvents were used. Stirring speed was also investigated since the 
chosen preparation method was largely based on stirring and stirring speed was expected to 
influence CFE.  Results obtained from the experimental design analysis are shown in Table 
4.10. 
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When the data obtained was subjected to mathematical modelling and fitted into a two factor 
interaction polynomial model and the polynomial equation relating Y, the response CFE (%) 
to the transformed factors, the following equation (model) (Equation 4.11) was obtained. 
 
Y = 46.02 + 6.16 X1 – 5.57 X2 – 2.86 X3 – 1.92 X1X3 - 2.92 X2X3  Eqn. 4.11 
 
The main effects (X1, X2 and X3) represented the average result of changing one factor at a 
time from its low to high value, while the interaction terms (X1X2, X2X3, and X1X3) showed 
how the response changed when two factors were simultaneously changed. This polynomial 
equation was then used to draw conclusions after considering the magnitude of the 
coefficient, the mathematical sign carried (i.e., positive or negative) and the p-value of the 
factor. Results of the mathematical modelling exercise are shown in Table 4.11. 
 
Table 4.11: Results of ANOVA analysis of factorial model 
Source                               Sum of squares            df          Mean squares    F value       P value 
                                                                                                                                              Prob > F 
 
Model                                     1428.31                      5                285.66            3.10             0.0076 
A – PC ratio                             606.39                      1                606.39            12.95           0.0049 
B – Stirring speed                    496.18                      1                496.18            10.59           0.0086 
C – organic solvent                  130.53                      1                130.53            2.79             0.1260 
AC                                              58.91                      1                 58.91             1.26             0.2883 
BC                                             136.1                       1               136.31            2.91             0.1188 
Lack of fit                                   4.49                        2                  2.25            0.039            0.9622 
 
The fitted model was considered adequate if it showed statistical significance (p < 0.05) and 
the lack-of-fit was not significant (p > 0.05). The data analysed showed a fairly good 
correlation with the model (p = 0.0076, R2 = 0.7531 and lack of fit p = 0.9622). Although the 
R2 value was only 0.7531, it was deemed suitable for the purpose of the model which was to 
investigate factors affecting CFE (Statease, 2016). However, R2 values close to 1 are 
important for purposes of optimising formulations. 
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The data (Table 4.11) showed that there were no significant interaction effects (i.e. X1X3, p = 
0.2883 and X2X3, p = 0.1188), but factors X1 and X2 were found to significantly affect CFE. 
Moreover, from Equation 4.11, X1 and X2 had a positive and negative sign, respectively, 
implying that an increase in PC content resulted in a corresponding increase in CFE while a 
decrease in stirring speed increased the CFE. On the other hand, the X3 factor had no 
significant effect on CFE, implying that irrespective of the organic solvent (i.e. 
tetrahydrofuran or dichloromethane) used, there were no noteworthy effects on the CFE. The 
relationship of factors X1 and X2 with CFE is further illustrated in Figures 4.13 and 4.14. As 
depicted by the response surfaces (Figures 4.13 and 4.14), increasing the PC amount resulted 
in an increase in CFE irrespective of type of organic solvent used. 
 
Figure 4.13: 3D representation of the effect of FDAE: PC ratio and stirring speed on CFE using 
dichloromethane 
 
 
Figure 4.14: 3D representation of the effect of FDAE: PC ratio and stirring speed on CFE using 
tetrahydrofuran 
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This was most likely effected by an increase in the number of PC binding sites available for 
interaction with the polar phytoconstituents of the extract. In this present study, where mass 
ratios were used, due to the complexity of the phytoconstituents, a further increase in the 
amount of PC may also have resulted in increase of the CFE. It is generally assumed that one 
polyphenol molecule complexes with one PC molecule (Kidd, 2009), therefore an increase in 
the amount of PC would have resulted in a subsequent improvement in the CFE, though, this 
would have been within limits of saturation. Indeed, saturation of choline molecules results in 
a decrease in the CFE as any additional phytoconstituents (i.e. in excess of choline 
molecules) will remain unbound hence the need to use experimental designs to optimise the 
preparation variables, particularly the PC quantity. 
 
One unique aspect of this drug delivery study was the complexation of a mixture of 
phytoconstituents with PC. The application of phytosome technology has generally thus far 
been with pure polyphenols and PC and the use of the stoichiometric ratio of 1:1. This ratio 
has been considered most suitable for formulating phytosomes (Khan et al., 2013). However, 
higher ratios of 1 : 3 have also yielded high encapsulation efficiencies of up to 94% (Pathan 
& Bhandari, 2011; Yue et al., 2010). In our unique scenario, to improve CFE, more PC 
interaction sites would therefore be required to interact with the numerous phytoconstituents 
as competition for interaction sites is high. 
 
The stirring speed (X2) also significantly affected the CFE (p = 0.0086). An increase in 
stirring speed decreased the CFE irrespective of the type of organic solvent used (Figures 
4.13 and 4.14). High stirring speeds reduce the contact time for the reactions to take place, in 
this case the hydrogen bond formation and or Van der Waals interactions between the choline 
head and the polar compounds. In addition, at high speeds (1000 rpm) it was noted that by the 
end of the 60 minutes of stirring most of the organic solvent had evaporated. The rate at 
which a solvent evaporates has been shown to affect CFE, where rapid evaporation rates 
result in low CFE and low speeds increase CFE (Yeo & Park, 2004). This study therefore 
supported this finding. 
 
In summary, based on the results from the experimental design, it was noted that in the 
preparation of A. afra phytosomes, the amount of PC and stirring speed significantly affected 
the CFE whereas the type of organic solvent used had no significant effects on the CFE. 
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4.4.2.3 Particle size, particle size distribution and colloidal stability of A. afra 
phytosomes 
Apart from an acceptable CFE, particle characterisation (i.e. determination of particle size, 
particle size distribution and colloidal stability) is a crucial aspect in drug product 
development and quality control of dosage forms. Results of the three characteristics for the 
A. afra phytosomes are shown in Table 4.12. 
 
Table 4.12: Particle size, polydispersity index (PDI) and zeta potential of A. afra 
phytosomes 
 
Particle size (nm)  Particle size distribution (PDI) Zeta potential (mV) 
487 ± 35    0.201 ± 0.076     -54.6 ± 0.2 
 
Firstly, the particle size of the phytosomes was in the nano range, thus increasing the surface 
area available for dissolution to occur, since, as per Noye-Whitney equation, the rate of 
dissolution is directly proportional to the surface area available for dissolution (Aulton & 
Taylor, 2013). In addition, the small size would also enable the phytosomes to penetrate into, 
and permeate through the physiological barriers (Saoji et al., 2016). 
 
Generally, PDI values of > 0.4 indicate extremely polydisperse systems which are 
undesirable, while mono-disperse systems ideally possess a PDI of 0 (Nobbmann, 2014). The 
phytosomes were moderately polydisperse (PDI = 0.1 – 0.4) and thus no significant effects 
on the dissolution, content uniformity, stability and bioavailability of the phytosome were 
expected. Broadly, polydisperse particles negatively affect the aforementioned parameters. 
With respect to dissolution, erratic drug release profiles are likely to occur as the polydisperse 
particles go into solution at contrasting rates. Similarly, content uniformity is also negatively 
affected as inconsistent amounts of the drug(s) will be present in the individual dosage forms. 
The phytosomes therefore had an acceptable PDI which was unlikely to adversely affect the 
dissolution and content uniformity. 
 
Zeta potential is a measure of the magnitude of the electrostatic or charge repulsion/attraction 
between particles, and is one of the fundamental parameters known to affect particle stability. 
The measurement brings detailed insight into the causes of dispersion, aggregation or 
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flocculation, and can be applied to improve the formulation of dispersions, emulsions and 
suspensions. The phytosomes had a zeta potential of -54.6 ± 0.2 mV, and a zeta potential 
greater than 30 mV or less than -30 mV indicates a stable colloidal system (Aulton & Taylor, 
2013). From the result obtained it could thus be concluded that the phytosomes formed a very 
stable colloidal system. 
 
Overall, the prepared phytosomes were of nanoparticle size and formed a moderately 
polydispersed but very stable colloidal system. 
 
4.4.2.4 Confirmation of phospholipid – phytoconstituent interaction 
The FTIR analytical technique was used to investigate spectroscopic characteristics which 
reflect the interactions between PC and the phytoconstituents bound in the complex and 
therefore confirm formation of the complex. The spectra result of the FTIR analyses of PC, 
phytosomes, physical mixture of the FDAE and PC, and FDAE are shown in Figure 4.15. 
 
 
Figure 4.15: FTIR spectra of phospholipids (A), phytosomes (B), physical mixture (C) and 
FDAE (D) 
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The FTIR spectrum of the phospholipids (A) contained the characteristic C-H stretching 
signal present in the long fatty acid chain at 2922 and 2853 cm-1, a C=C stretching band at 
3010 cm-1 representing the internal fatty acid alkene, the C=O stretching band in the fatty 
acid ester at 1737 cm-1 and, a P=O stretching band at 1236 cm-1 and a P-O-C stretching band 
1060 cm-1 for the choline (Saoji et al., 2016). 
 
For the FDAE, a broad peak at 3260 cm-1, representing an –OH group substituted on an 
aromatic ring, common with flavonoids was present (Khan et al., 2014). In addition a weak 
C-H stretching signal at 2919 cm-1 relating to the short aliphatic chains typically found in 
some flavonoids and glycosides was present as well as an aromatic ring stretch C=C-C, 
exhibited at 1594 cm-1, which related to the presence of aromatic constituents such as 
flavonoids, tannins and saponins (Sikarwar et al., 2008). 
Finally, the FTIR spectrum of the complex was quite different, particularly in the fingerprint 
region (i.e. 1600 to 650 cm-1), from that of the phospholipids, physical mixture and FDAE. 
Compared to the phospholipid spectrum, there was a slight shift of the P-O-C absorption 
band from 1060.25 to 1059.80 cm-1, disappearance of a peak at 1616.04 cm-1 and a change in 
shape of the spectra around 970 cm-1 thus confirming interaction of the polar head of PC and 
the phytoconstituents. 
 
The FTIR thus provided evidence of the formation of phytosomes and also confirmed that the 
formation was through interactions between the phospholipid polar head and the 
phytoconstituents. 
 
4.4.2.5 Particle shape and surface morphology 
The shape and surface morphology of the phytosomes was analysed using the SEM and the 
results data of this analysis are depicted in Figure 4.16. The phytosomes appeared spherical 
with a smooth surface and were generally all of the same size (mono-dispersed). The 
spherical shape was advantageous as it increased the surface area available for dissolution 
and, improved both drug release properties and flow properties of the phytosomal powder. 
Based on the dynamic light scattering method, the particle size was approximately 487 nm, 
while the SEM image indicated a much smaller size of about 70 nm. This discrepancy may 
have been due to the micelles that form when the phytosomes were in the aqueous media 
causing the larger size in contrast to the SEM image for which the dry powder form of the 
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phytosomes was used and, the zeta potential value of -54.6 mV eliminated any chances that 
the discrepancy could have been due to aggregation of the particles. 
 
Generally, SEM images of phytosomes from other studies have shown them to either be rod 
shaped (Das & Kalita, 2014) or irregularly shaped (Arora, Sharma & Kaur, 2013; Habbu et 
al., 2013; Sabzichi et al., 2014), i.e. different to that found in the present study.  This may 
have been due to the preparation techniques used which, in most cases, were either reflux or 
solvent evaporation methods. The stirring or homogenisation based preparation techniques, as 
used in the present study, generally yield spherical shapes. 
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Figure 4.16: Scanning election microscope images of A. afra phytosomes 
 
Overall, the phytosome shape and surface morphology were spherical and smooth, 
respectively, characteristics which were both ideal for pharmaceutical powders. 
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4.4.2.6 Apparent solubility of the FDAE and phytosomes 
The apparent solubility of the FDAE and phytosomes, using luteolin as a marker compound, 
was determined in water and octanol at 25oC and the results obtained are shown in 
Table 4.13. 
 
The results indicated that complexation of phytoconstituents with PC significantly 
(p < 0.0001) decreased the water solubility of the phytoconstituents and significantly 
(p = 0.001) improved their lipid solubility. Several other authors have also noted the 
improved lipophilicity associated with phytosomes (Khan et al., 2014; Zhao et al., 2013). 
Phosphatidylcholine is an amphipathic molecule, having a positively charged head group and 
two neutrally charged tail groups, that renders it miscible in both water and lipid 
environments. By complexation of phytoconstituents with PC to make the phytosomes, the 
phytoconstituents come to share some of the PC’s versatile solubility properties as evidenced 
by the results in Table 4.13. In this interaction the polar PC head is responsible for the water 
solubility while the tail groups are responsible for lipid solubility. 
 
Table 4.13: Apparent solubility of luteolin in the FDAE and A. afra phytosomes in water 
and n-octanol at 25oC 
 
Apparent solubility (µg/ml) * 
Water   n-octanol 
FDAE      13.62 ± 0.54  0.27 ± 0.18   
A. afra phospholipid complex  0.23 ± 0.003  1.35 ± 0.004 
*n = 3 
Extrapolating from the FTIR results, which showed that the phytoconstituents interacted with 
the polar head of the PC, the diminished water solubility of the phytosomes could be 
explained by the decreased availability of PC polar head molecules to form hydrogen bonds 
(an important determinant of water solubility) with water molecules. The ostensibly improved 
lipophilicity could thus be attributed to the enwrapping of the bound phytoconstituents by the 
two aliphatic tails to produce a lipophilic envelope which allows the complex to dissolve in 
low polarity solvents (Bombardelli 1989).  
 
http://etd.uwc.ac.za/
77 
 
In summary, lipophilicity is an important determinant in the prediction of the absorption of 
substances and therefore from the apparent solubility findings of this study it can be deduced 
that phytosomes significantly improved the lipophilicity of the A. afra phytoconstituents and 
therefore, potentially also improve their absorption. 
 
4.5 Conclusion 
 
The objectives of this study were to prepare and characterise A. afra FDAE and phytosomes 
thereof. From the results obtained the following conclusions could be drawn; 
 
Moderate yields of the FDAE were obtained and the extract was well characterised, showing 
good aqueous solubility, acceptable moisture content and a high flavonoid content. Also the 
extract contained moderate levels of luteolin, mostly in the conjugate form. However, the 
FDAE was hygroscopic and poorly lipid soluble. The HPLC method developed for the assay 
of luteolin proved to be sufficiently accurate and reproducible for the quantitative analysis of 
luteolin in the A. afra FDAE and phytosomes. Furthermore, the mechanical dispersion 
method was suitable for the preparation of A. afra phytosomes and yielded phytosomes with 
a good CFE and with suitable pharmaceutical physicochemical characteristics - smooth, 
spherical, mono-dispersed, nano-sized particles which had good colloidal stability and 
improved lipid solubility. However, the CFE was significantly affected by the 
phosphatidylcholine amount and stirring speed. 
 
In conclusion, phytosome technology can be successfully implemented on the FDAE of A. 
afra to produce a phytosome delivery product having acceptable pharmaceutical 
physiochemical characteristics and improved lipophilicity suitable for drug delivery. 
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Chapter 5 
 
Evaluation of drug release properties of Artemisia afra 
preparations: FDAE and phytosomes 
             
 
5.1 Introduction 
One of the objectives of this study was to compare the dissolution profiles of A. afra FDAE 
versus the phytosomes, in simulated gastric and/ intestinal fluid, using luteolin as the marker 
compound. In this chapter, the materials, equipment, methodology and procedures used to 
determine the dissolution of A. afra FDAE and phytosomes are presented. Included among 
the procedures explained is the comparison of dissolution profiles and evaluation of the 
luteolin release mechanisms and kinetics of the aforementioned preparations.  
 
5.2 Equipment and materials 
 
5.2.1 Equipment 
The following equipment was used; 
Square hot plate magnetic stirrer (Dragonlab, Model MS7-H550 Pro, Dragon 
Laboratories, China), vacuum pump (Buchi, Model V-500, BuchiLarbotechnik AG, 
Switzerland), Whatman No. 1 paper filter, 5 ml syringes, nylon syringe filters (25 mm 
diameter, 0.45 µm pore size), micropipettes, HPLC filter unit (Millipore Cameo 25 AS, 
DDA 02025So MSI: Micro separation Inc., USA), membrane filters (Durapore, 0.45 µm 
HV, Millipore), semi automated dissolution tester with fraction collector, micro glass 
filters (Sotax AT7-Smart, Switzerland), pH meter (Basic 20,Lasec, South Africa) 
The HPLC system (Agilent, Model 1200 series, Chemetrics) used consisted of a vacuum 
degasser (Agilent 1200 series, Model G1322A, Germany), autosampler (Agilent 1200 series, 
Model G1329A, Germany), thermostatted column compartment (Agilent 1200 series, 
Model G1316A, Germany), a quaternary pump (Agilent 1200 series, Model G1311A, 
Germany), a diode array detector (DAD) (Agilent 1200 series, Model G1315B, Germany), a 
PC with Chemstation® software (Agilent, OpenLAB CDS Chemstation Edition LC and CE 
version A.01.04(033)) and a reverse phase column (Luna® 5 μm, C18, 250 x 4.60 mm, 
Phenomenex, United States of America). 
 
http://etd.uwc.ac.za/
79 
 
5.2.2 Materials 
Phytosomes and FDAE of A. afra (prepared from previous chapter) 
 
5.2.3 Chemicals 
The following chemicals were used; 
Acetonitrile (HPLC grade), methanol (HPLC grade), sodium nitrate, aluminium chloride 
(Merck, Darmstadt, Germany), formic acid (BDH Chemicals Ltd, England), hydrochloric 
acid 32% w/v (Kimix, USA), sodium hydroxide pellets, anhydrous dibasic sodium 
phosphate, disodium hydrogen orthophosphate (Merck, SA); Triton X-100 (Sigma 
Aldrich, USA); distilled water (Millipore, Milford, MA, USA). 
 
5.3 Methods 
5.3.1 Determination of the dissolution profile of the A. afra FDAE 
The USP basket apparatus method was used to determine the dissolution of the A. afra 
phytoconstituents (using marker compounds, luteolin and TFC) from the FDAE in 0.1 N 
hydrochloric acid (pH 1.2).  
 
Briefly, approximately 1 000 mg of the FDAE was weighed in each of the six baskets to 
ensure content weight uniformity in compliance with the USP guidelines. Standard 
procedures were used to prepare the dissolution media (Appendix 6) and the final pH was 
confirmed using a calibrated pH meter. For the dissolution tests, each vessel contained 
approximately 1 000 mg of extract in 450 ml of 0.1 N hydrochloric acid at 37 ± 0.5oC and 
stirred at 100 rpm. At predetermined time intervals (5, 10, 15, 20, 30, 45, 60, 90 and 120 
minutes), 5 ml of sample was automatically withdrawn from each vessel through an in-line 
glass filter and replaced with an equal volume of the same pre-warmed (37 ± 0.5oC) medium 
in order to maintain sink conditions. Aliquots were then taken from each 5 ml sample and 
used to determine the concentrations of free and total luteolin, and TFC dissolved at the 
various time points.  
 
To determine the free luteolin dissolved at each time point, 20 µl was injected into the HPLC 
system analysed using the validated HPLC method reported in section 4.3.1.2.5. In the 
determination of the total (hydrolysed) luteolin dissolved at the various time points (5, 15, 30, 
60 and 120 minutes), 1 ml of the dissolution sample was hydrolysed using the method 
described in section 4.3.1.2.6 and analysed also using the previously mentioned validated 
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HPLC method. Finally, to determine the TFC dissolved at 5, 15, 30, 60 and 120 minutes, 1 
ml of the dissolution sample was analysed using the method described in section 4.3.1.2.4. 
The amount and percentage of free and total luteolin, and TFC dissolved was calculated from 
the peak area response of the HPLC chromatograms, using the highest peak response 
obtained from each vessel as the 100% value. The data was plotted as percentage dissolved ± 
standard deviation versus dissolution time using GraphPad Prism 6. 
 
Lastly, to compare the dissolution profiles of free and total luteolin, and TFC from the FDAE, 
the f2 and ANOVA methods were used. The f2 values were calculated according to 
Equation 5.1 using the DDSolve® software. 
 
   Eqn 5.1 
 
Where, the parameters, Rt and Tt are the mean percent dissolved at each time point for the 
reference and test products, respectively, and n is the number of observations /dissolution 
sample times being considered for the computation and Wt is an optional weight factor.  
 
Comparison by ANOVA was determined using the DDSolve® software, where it compared 
corresponding time points and significance level was set at p < 0.05. 
 
5.3.2 Determination of the dissolution profile of the A. afra phytosomes 
The methodology was based on the physiological and physicochemical properties controlling 
drug absorption of phytosomes. Similar to the FDAE dissolution test, the USP basket 
apparatus was used in the dissolution test of the phytosomes.  
 
The dissolution test was designed in a manner that mimicked the passage of the phytosomes 
through the gastrointestinal tract and the conditions thereof and, taking into consideration the 
lipophilicity of the phytosomes, USP delayed release method A was implemented. Briefly, 
the method consisted of an acid stage in 0.1 N hydrochloric acid (pH 1.2), that mimicked the 
stomach environment and a buffer stage (pH 6.8). The buffer stage was modified to mimic 
the small intestines and bile salts (which are an integral part of the absorption of lipids), and 
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contained a surfactant (Löbenberg & Amidon, 2000), 4% Triton X-100 phosphate buffer 
solution at pH 6.8. The surfactant was selected on the basis of FDA approval and its use in 
dissolution studies of other drugs such as ergocalciferol, alectinib, and carbozantinib (U.S. 
Food and Drug Administration, 2016). The concentration of 4% v/v (4.28% 
w/v) was used as it 
was above the critical micelle concentration (0.0155% w/v). 
 
For the dissolution procedure, briefly, approximately 1 000 mg of phytosomes were weighed 
into each of the six baskets, vessels were filled with 450 ml of 0.1 N hydrochloric acid and, 
allowed to equilibrate to 37 ± 0.5oC, the phytosome loaded baskets placed in dissolution 
medium and rotated at 100 rpm. After 2 hours of operation, a 10 ml aliquot was automatically 
withdrawn through an in-line glass filter and stored at 4oC for analysis. Immediately after 
withdrawing the aliquot and with the apparatus operating, 150 ml pre-warmed buffer (16% 
Triton X-100) was added and pH adjusted to 6.8 ± 0.05 within 5 minutes using 2 N 
hydrochloric acid or 2 M NaOH. Further 10 ml aliquots were then withdrawn at 2.5, 3.0, 4.0, 
6.0, 8.0, 10.0 and 12.0 hours post start of the dissolution test. After each sample withdrawal 
an equivalent volume of fresh pre-warmed dissolution medium was added to maintain sink 
conditions. The replacement medium for the buffer stage was a mix of the acid and buffer 
media, and surfactant so as to mimic the initial buffer stage conditions to which the buffer 
was added to the acid stage. The pH of the replacement medium was adjusted to pH 6.8. 
 
From each of the collected dissolution samples, 5 ml was withdrawn and placed in a 10 ml 
test tube, 3 ml ethyl acetate added, the mixture vortexed for 60 seconds and centrifuged at 
5 000 rpm for 5 minutes. Thereafter, the ethyl acetate layer was pipetted into a separate 10 ml 
test tube, blown dry under a gentle stream of nitrogen and 100 µl of methanol added to the 
residue. The tube was gently swirled until the residue was uniformly mixed and finally 20 µl 
injected into the HPLC system for luteolin quantification using the validated HPLC method 
reported in 4.3.1.2.5.  
 
The amount and percentage of luteolin dissolved was calculated from the peak area responses 
of the HPLC chromatograms, using the highest peak response obtained from each vessel as 
the 100% value. Data was plotted as percentage dissolved ± standard deviation versus 
dissolution time and Q-release were determined using GraphPad Prism 6. 
 
http://etd.uwc.ac.za/
82 
 
5.3.3 Comparison of dissolution profiles of A. afra FDAE versus phytosomes 
To compare the dissolution profiles of luteolin from the FDAE and phytosomes, two methods 
were employed. These were the ratio of percent dissolved (Q-values) and ratio of mean 
dissolution time (MDT) methods, both being model independent methods. Firstly, The Q-
values were determined from the dissolution profiles by simply deriving the time taken for 
75% of the luteolin to be released into solution (Q75) and for this GraphPad Prism 6 was used. 
Secondly, the MDTs were calculated according to Equation 5.2, using the DDSolve® 
software. 
 
    Eqn 5.2 
 
where, i is the dissolution sample number (e.g., i = 1 for 5-min data, i= 2 for 10-min data, 
etc.), n is the number of dissolution sample times, tmid is the time at the midpoint between i 
and i-1, and ∆M is the additional amount of drug dissolved between i and i-1. 
 
Finally, the Q-values and MDTs were compared by ANOVA and significance level was set at 
p < 0.05. 
 
5.3.3.1 Determination of the luteolin release mechanism from A. afra FDAE and 
phytosomes 
The luteolin dissolution profiles of FDAE and phytosomes were also compared by means of 
release mechanisms and kinetics. For this, Weibull, Probit, Logistic, Makoid-Bakanar, 
Peppas-Sahlin and the  Korsmeyer-Peppas models, and analysis using DDSolve® software 
(Zhang et al., 2010), were employed and the best fit model selected on the basis of the lowest 
AIC. 
5.4 Results and discussion 
5.4.1 Dissolution of luteolin and TFC from A. afra FDAE 
Initially, 1 000 mg of extract was immersed in 900 ml of dissolution medium but due to the 
low content of free luteolin in the plant material (< 0.5 mg/g), as well as to improve the 
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sensitivity of the method by increasing marker compound concentration, the dissolution 
medium was reduced to 450 ml, maintained at 37 ± 0.5oC. The dissolution profile of free 
luteolin obtained is shown in Figure 5.1. 
. 
Figure 5.1: Dissolution profile of luteolin aglycone from A. afra FDAE at pH 1.2. 
Data is presented as mean ± SD (n = 6) 
 
Although there are no pharmacopoeia specifications for the dissolution of A. afra 
preparations, the acceptance criteria set was based on the BP 2013, viz. that at least 75% of 
the marker compound be released within 45 minutes for immediate release dosage forms. 
Therefore, from the dissolution profiles, the percentage of luteolin dissolved at 45 minutes 
was determined in order to classify the release as immediate (Q75 ≤ 45 minutes) or otherwise. 
 
The Q75 value for free luteolin from the A. afra FDAE was less than 20 minutes (Table 5.1). 
This was illustrative of an immediate release profile as the time was much shorter than the 
45-minute specification for immediate release classification. This was expected as the extract 
was aqueous based. Furthermore, the partition coefficient and apparent solubility values 
(sections 4.4.1.8 and 4.4.2.6, respectively) showed that the extract was hydrophilic hence also 
the burst release dissolution profile obtained. The results were similar to those obtained by 
Max (2007), in which more than 75% of the extract was released within 30 minutes (Max, 
2007). In addition, the same immediate release characteristic was obtained by Komperlla 
(2004) where more than 70% of the tabletted extract was dissolved within 45 minutes 
(Komperlla, 2004). 
 
The release profile of free luteolin from the extract was rather irregular with wide variations 
(mean RSD = 35%). This behaviour may be attributed to the different forms of luteolin 
present in the extract i.e. free and conjugated and their stability in the acidic medium. The 
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conjugate forms of luteolin may act as a reservoir that releases luteolin upon hydrolysis hence 
the fluctuating luteolin levels. On the contrary, this irregular trend was not evident in the total 
luteolin release profile (Figure 5.2). 
 
Figure 5.2: Dissolution profile of total (hydrolysed) luteolin from A. afra FDAE 
at pH 1.2. Data is presented as mean ± SD (n=6) 
 
Similar to the free luteolin dissolution profile, the total luteolin release was also immediate, 
with 75% of the total luteolin being released within 20 minutes (Table 5.1). However, the 
total luteolin profile was more consistent than that for the free luteolin. This may have been 
due to a fewer number of sampling time points in the data profile such that inconsistencies 
may have been omitted. Also, because the sample was hydrolysed, it was less likely to be 
prone to fluctuations arising from conjugate forms of luteolin. After the 60-minute sampling 
point the dissolution profile also showed a gradual decrease in total luteolin released and one 
probable explanation for this may be the instability of luteolin in these acid conditions. 
 
The TFC release profile was also assessed and it revealed a rapid release profile similar to the 
aforementioned profiles, with 75% of the total flavonoids being released in 15 minutes 
(Table 5.1).  
 
Table 5.1: Classification of A. afra FDAE by dissolution rate 
 
 
Q = 75% 
(minutes) 
Dissolution 
characteristic 
Free luteolin 16 Immediate release 
Total luteolin 15 Immediate release 
TFC 13 Immediate release 
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The profile was rather consistent with a slight decrease in total flavonoids released post the 
60-minute sampling point. Interestingly, this decrease was also the case for the total luteolin 
release profile, though that decrease was more evident in the TFC profile thus further 
supporting the instability of flavonoids under acidic gastric conditions. 
 
 
Figure 5.3: Dissolution profiles of total flavonoid content (TFC) from A. afra FDAE at pH 1.2. 
Data is presented as mean ± SD (n =6) 
 
The superimposed free luteolin, total luteolin and TFC profiles (Figure 5.4), showed that the 
release of all the marker compounds appeared almost identical. 
 
Figure 5.4: Dissolution profiles of free and total luteolin, and TFC from A. afra FDAE at pH 1.2. 
Data presented as mean ± SD (n=6) 
 
Nevertheless, to quantitatively assess the similarity or dissimilarity of the dissolution profiles, 
the similarity factor (f2) and univariate ANOVA analysis were employed to compare the 
profiles. A summary of the comparison results is shown in Table 5.2 while the detailed 
ANOVA results are shown in Appendix 4. 
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Table 5.2: Comparison of dissolution profiles of A. afra using different marker 
compounds 
 Similarity factor+ 
(f2) 
ANOVA 
(p-value) 
Free versus total luteolin 53 Not significant 
Free luteolin versus TFC N/A 0.0484* 
Total luteolin versus TFC N/A 0.0272* 
+ Bootstrapping similarity factor 
*Significant difference was only at the 30-minute time point 
 
The dissolution profiles of free and total luteolin were similar (f2 > 50) and from the ANOVA 
results, all corresponding time points were not significantly different (p > 0.05) from each 
other. The expectation was that the total luteolin dissolution might be faster than the free 
luteolin because the luteolin conjugates are known to be more water soluble than the 
aglycone forms (Evans, 2009), but both were very rapid, i.e. > 80% released at 20 minutes. 
 
The f2 could not be used to compare the TFC dissolution profile with the free and total 
luteolin profiles as they are different chemical entities hence ANOVA was used. The TFC 
dissolution profile was generally similar to those of free and total luteolin with only 
significantly different 30-minute time points. Based on these results, either of the marker 
compounds was suitable for use as a quality control marker for the dissolution of the FDAE 
of A. afra as the dissolution profiles of the marker compounds were all similar, with no 
significant differences. 
 
It is important to highlight that the immediate (burst) release of the phytoconstituents from 
the plant matrix may be undesirable therapeutically (Costa et al., 2011). Due to the low 
partition coefficient and n-octanol apparent solubility, the rapid phytoconstituent release is 
not favourable for the FDAE of A. afra as ideal plasma concentrations may be not be attained 
due to inadequate time for absorption and their low lipophilicity. In addition, the rapid release 
may lead to dose dumping which in turn may result in the body being unable to absorb all the 
A. afra active constituents thus affecting the extracts’ efficacy due to inability to maintain 
ideal plasma concentrations necessary for the desired therapeutic outcome. Lastly, such rapid 
release profiles may also lead to toxicity due to the large dose that is released over a short 
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period of time, hence the second objective of the study, viz. to modify the release profile of 
the A. afra phytoconstituents. 
 
All in all, the A. afra FDAE exhibited a very rapid release profile and this was true for all the 
flavonoid marker compounds, i.e. free and total luteolin and TFC, measured. 
 
5.4.2 Dissolution of A. afra phytosomes 
From the previous chapter, the phytosomal preparation was shown to significantly improve 
the lipophilicity of the A. afra phytoconstituents and this physicochemical characteristic was 
likely to have an effect on the dissolution of the phytoconstituents. It was therefore 
hypothesised that there would be a decrease in the dissolution rate of the phytosomes in 
comparison to that of the FDAE. This section therefore looked into the effect the phytosomal 
dosage form had on the dissolution profile of the A. afra phytoconstituents. 
 
In view of the physicochemical characteristics of the phytosomes, it was noted that they 
possessed poor flow properties hence no capsule filling was done and the phytosomes were 
filled directly into the dissolution baskets. 
 
Also, due to the lack of complexation between luteolin conjugates and the phospholipids (see 
section 4.4.2.1), the dissolution of the total (hydrolysed) luteolin could not be measured. 
Similarly, the dissolution profile of the TFC also could not be measured, possibly due to the 
presence of Triton X-100 which may have interfered with the determination or, alternatively, 
due to low concentrations of the flavonoids in the dissolution vessel. However, the 
dissolution profile obtained for the free luteolin from the phytosomes could be measured and 
is shown in Figure 5.5. 
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Figure 5.5: Dissolution profile of free luteolin from A. afra phytosomes. Red section represents 
the acid stage and black section represents buffer stage. Data is presented as 
mean ± SD (n= 6) 
 
The dissolution profile of free luteolin from the phytosomes showed a delayed and extended 
release profile. The USP acceptance criterion for a delayed release is not more than 10% 
released by the 2-hour sampling point (USP 36, 2004). In this study, 8.6% had been released 
by the 2-hour mark thus the luteolin release from the A. afra phytosomes fitted into the 
delayed release criterion. The 2-hour sampling point also served to check for the presence or 
absence of dose dumping, which in this case was absent. Post the 2-hour mark and in the pH 
6.8 (or simulated intestinal medium), there was a sudden release of luteolin which then 
steadied after the 2.5-hour sampling point until it slowed and plateaued around the 8-hour 
mark. 
 
All in all, only the dissolution of free luteolin could be measured from the A. afra phytosomes 
and it showed a typical delayed and extended release profile with no dose dumping being 
evident. 
 
5.4.3 Comparison of luteolin dissolution profiles of A. afra FDAE and phytosomes 
The luteolin release from the phytosomes was consistent in contrast to that of free luteolin 
from the FDAE. This may have been due to complexation (between phospholipids and 
phytoconstituents) which controlled the amount of phytoconstituents that went into solution 
or possibly due to the absence of luteolin glycosides which would act as an ‘extra’ source of 
luteolin thereby resulting in fluctuations as those observed in Figure 5.1. 
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The Q75 and mean luteolin dissolution time (MDT) of the phytosomes were 366 and 269 
minutes, respectively, as shown in Table 5.3. These Q75 and MDT values for the phytosomes 
were significantly (p < 0.05) different from those obtained for the FDAE, thus proving that 
the release of luteolin from the FDAE had been successfully modified. 
 
Table 5.3: Comparison of Q75 values and MDTs of luteolin release from A. afra FDAE 
and phytosomes 
 
 
 
Q = 75% 
(minutes) 
Dissolution 
characteristic 
MDT 
(minutes) 
FDAE  16 Immediate release 18.9 
Phytosome 366 Delayed release 269.4 
 p < 0.05                                        p < 0.01 
 
Complexation of active constituents(s), e.g. with cyclodextrin, is a technique that has been 
widely used to alter their physicochemical and physiological properties (Jackson, Young & 
Pant, 2000). In this present study, the alteration of the dissolution profile of the 
phytoconstituents was hinged upon the decreasing water solubility (increasing lipophilicity) 
by complexation of phytoconstituents with phospholipids, thus from the comparison above, 
the dissolution rate of the phytoconstituents was successfully decreased. 
 
Interestingly, the phytosome complex possibly imparted a gastro protective effect on the 
phytoconstituents of A. afra, thus conferring acid stability to the constituents (Singh et al., 
2011a). This is of importance as the majority of the flavonoids in A. afra are in the conjugate 
form, which under gastric acidic conditions may be hydrolysed to the aglycone form (Manach 
et al., 2004). Glycosides have been associated with pharmacological actions hence their 
protection from hydrolysis is of great importance. 
 
In addition to the delayed release which imparted improved gastric acid stability to the 
phytoconstituents, the extended release during the buffer stage was also beneficial. Extended 
release mechanisms are advantageous in that they reduce dosing frequency and quantity, 
improve absorption and bioavailability. These are all aspects that the FDAE lacked and 
therefore the phytosome drug delivery system addressed most of the flaws of the FDAE in 
addition to the primary goal of modifying the release of the phytoconstituents.  
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Phytosomes have been used as a mechanism to improve the aqueous solubility of poorly 
soluble drugs in many studies (Pathan & Bhandari, 2011; Arora, Sharma & Kaur, 2013; 
Habbu et al., 2013; Zhao et al., 2013; Das & Kalita, 2014; Khan et al., 2014; Singh et al., 
2014), but in this present study the contrary was performed, i.e. phytosome technology was 
used to decrease aqueous solubility (decrease dissolution rate). In a similar study, that had the 
same objective of reducing the dissolution rate of an active ingredient, a controlled release 
pattern was shown by the gallic acid complex (which showed continuous release up to 93% 
of gallic acid) at the end of 24 hours in comparison to free gallic acid (which showed 81.9% 
burst release in just 0.5 hours) (Singh et al., 2011b). The results of the aforementioned study 
therefore support the findings of this present study. 
 
In summary, the use of the phytosome technique was effective in retarding the dissolution 
rate of the hydrophilic phytoconstituents of A. afra and therefore successfully modified the 
release of the phytoconstituents.  
 
5.4.3.1 Kinetics of luteolin release from A. afra FDAE and phytosomes  
It was however also important to further discern the kinetics and mechanism of release 
involved in the dissolution of the luteolin from the phytosomes and FDAE, so as understand 
the underlying processes involved. To elucidate the mechanisms behind the release of the 
aglycone marker compound, luteolin, from the A. afra preparations, the dissolution data 
obtained were fitted to mathematical models. This section describes the results obtained from 
such mathematical modelling of the marker compound release from the two preparations. 
 
Generally, the free and total luteolin, and TFC dissolution data for the FDAE of A. afra best 
fitted the Peppas-Sahlin model (Figure 5.6 and Appendix 5). This was shown by the lower 
AIC values compared to that for the other models, which implied better model suitability. 
The AIC values and model parameters obtained are shown in Appendix 5. 
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Figure 5.6: Model (Peppas-Sahlin 1 with Tlag) of best fit for in vitro release of TFC (A), free 
luteolin (B) and total luteolin (C) from A. afra FDAE at pH 1.2. Results are 
mean ± SD (n =6).  
 
Peppas-Sahlin models describe release occurring via two mechanisms, namely, Fickian 
diffusion and matrix relaxation/erosion and their contribution is denoted by the k1 and k2 
constants, respectively. The k1 values for free and total luteolin, and TFC were 49.413, 
54.706 and 69.717 respectively, whereas the k2 values were all negative. This therefore 
indicated that the release mechanism of the marker compounds was exclusively by Fickian 
diffusion.  
 
Similar to this present study, an investigation of the release mechanism of flavonoids 
(sutherlandins) from different Sutherlandin frutescens plant materials, also reported that some 
of that data fitted the Peppas-Sahlin model, but in contrast to findings of the present study, 
their k1 and k2 constants showed that the release mechanism was due a combination of both 
Fickian diffusion and matrix relaxation/erosion (Mbamalu, 2015). 
 
In order to establish the suitability of the marker compounds for their use in dissolution tests 
of the A. afra extract, the Fickian constants were compared, i.e. the k1
free luteolin 
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versus k1
total luteolin, k1
free luteolin versus k1
TFC and k1
total luteolin versus k1
TFC. No significant 
differences (p > 0.05) were observed implying that use of either of the marker compounds 
gave a good representation of the dissolution of the phytoconstituents of the extract. This was 
also confirmed by the results (Table 5.2) obtained through statistical (ANOVA) and model 
independent (f2) comparisons where no significant differences in the dissolution profiles of 
the marker compounds (free and total luteolin and TFC) under gastric conditions (pH 1.2) 
were found. 
 
The luteolin dissolution data of the phytosomes fitted well (R2adj > 0.9300) into several 
models viz. Probit, Logistic, Makoid-Bakanar with Tlag, Korsmeyer-Peppas with Tlag and 
Weibull models (Appendix 5). Of these, the Weibull model gave the best fit as it had the 
lowest AIC value (Appendix 5). Generally, the Weibull model has been found to fit most 
dissolution data curves (Costa & Lobo, 2001) and the data of the present study was no 
exception (Figure 5.7). 
 
 
Figure 5.7: Model of best fit (Weibull_4) for in vitro release of luteolin from A. afra phytosomes. 
Results are Mean ± SD. (n = 6) 
 
With a Weibull function, β, of 2.188 the shape of the luteolin dissolution curve was sigmoid 
and indicated that the release of luteolin from the phytosomes was by a complex mechanism. 
Overall, the rate of release did not change monotonically but rather initially increased 
nonlinearly up to an inflection point and thereafter decreased asymptotically. To further 
elucidate the mechanism of release, the data was also fitted to the Korsmeyer-Peppas model 
(R2adj = 0.9750) and yielded an n value of 1.367 (Appendix 5). This n value indicated a super 
case II transport mechanism which is a relaxational release similar to the complex release 
mechanism suggested by the obtained Weibull function. The Korsmeyer-Peppas model data 
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therefore also verified that the Weibull function, β may be accurately used to describe the 
release mechanisms of luteolin from A. afra phytosomes (Papadopoulou et al., 2006). 
 
Finally, comparison of the release mechanisms of luteolin from the FDAE and phytosomes 
revealed a clear difference as release from the former was by Fickian diffusion but from the 
latter, by a complex mechanism. It therefore further confirmed that the phytosome 
complexation technique modifies the release of the phytoconstituents not only in terms of 
dissolution time but also in terms of release mechanism and kinetics.  
 
5.5 Conclusion 
The overall objective of the chapter was to test the hypothesis that phytosomes of A. afra 
could modify the release profile of the phytoconstituents by decreasing their dissolution rate. 
From the results obtained the following conclusions could be drawn. 
 
Free and total luteolin and TFC were suitable for use as quality control markers for the 
dissolution of the FDAE of A. afra. The dissolution of phytoconstituents of A. afra, using 
luteolin as the marker compound, was significantly modified from a very rapid immediate 
release in the FDAE form to a delayed and extended release profile in the phytosomal dosage 
form. Also, in terms of release mechanism, free and total luteolin, and TFC were all released 
from the FDAE through Fickian diffusion but luteolin was released from the phytosomal 
complex through a complex mechanism. 
 
In summary, phytosome complexation technique can be successfully used to decrease the 
dissolution rate and modify the release mechanism of phytoconstituents of A. afra. 
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Chapter 6 
 
Conclusions and recommendations 
             
The overall aim of this study was to modify the in vitro release of Artemisia afra 
phytoconstituents in simulated gastrointestinal conditions using the phytosome drug delivery 
technique. The specific objectives were to prepare and characterise A. afra phytosomes, 
identify factors influencing the efficiency of complex formation between the A. afra 
phytoconstituents and phospholipids and, ultimately evaluate the phytosome dissolution 
profile in comparison to the A. afra freeze dried aqueous extract dissolution profile.  
 
It was hypothesised that the phytosome technique could be successfully effectuated on the 
freeze dried aqueous extract of Artemisia afra to produce a phytosome drug delivery system 
having acceptable pharmaceutical physicochemical properties and, that the dissolution rate of 
phytoconstituents from such phytosomes would be lower than that of the freeze dried 
aqueous extract. 
 
From the results obtained the following major conclusions could be drawn; 
 
1. The mechanical dispersion method was suitable for the preparation of A. afra 
phytosomes and produced phytosomes with good complex formation (CFE) and with 
suitable pharmaceutical physicochemical characteristics - smooth, spherical, mono-
dispersed, nano-sized particles which had good colloidal stability and improved lipid 
solubility.  
2. In the preparation of the A. afra phytosomes, the CFE was significantly affected by 
the phosphatidylcholine amount and stirring speed, where it directly varied with the 
former and inversely varied with the latter. However, the type of organic solvent used 
had no significant effect of the CFE. 
3. The dissolution of phytoconstituents of A. afra, using luteolin as the marker 
compound, was significantly modified from a very rapid immediate release in the 
FDAE form to a delayed and extended release profile in the phytosomal dosage form. 
Also, in terms of release mechanism, luteolin was released from the FDAE through 
Fickian diffusion in contrast to the release of luteolin from the phytosomal complex 
which was by a complex mechanism. 
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In summary, the phytosomal drug delivery technique is suitable for use in the delivery of 
Artemisia afra phytoconstituents and the technique is capable of modifying the 
phytoconstituent release profile so as to allay the challenges associated with immediate 
release profiles. 
 
From the results, further areas of research were noted. Firstly, the A. afra phytosomes were 
sticky and non free flowing thus posing challenges in the manufacturing and handling 
processes such as capsule filling and hence there is need to formulate them with other 
excipients such as silicone dioxide, microcrystalline cellulose and magnesium stearate to 
improve the flow properties. Secondly, the complex formation efficiency was nowhere near 
100% and some phytoconstituents such as luteolin glycosides, did not complex with the 
phospholipids. It is therefore necessary to optimise the preparation technique so as to improve 
the complex formation efficiency and ensure all phytoconstituents complex with the 
phospholipids. Thirdly, there is need to conduct in vivo studies on the absorption of the 
Artemisia afra phytosomal complex to verify if the intestinal permeability and bioavailability 
does improve as a result of the increased lipophilicity of the phytoconstituents. Finally, the 
pharmacological activity of the Artemisia afra phytosomes should also be evaluated to ensure 
the desired pharmacological activity is maintained or enhanced with the phytosome delivery 
system in contrast to the FDAE. 
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Appendices 
 
Appendix 1: Extractions conducted and resultant yields obtained in the preparation of 
the freeze-dried aqueous extracts of Artemisia afra. 
 
Mass of leaves (g) Volume of water 
(ml) 
Mass of FDAE (g) Yield of extract (%) 
20.057 
11.500 
100.890 
102.400 
25.000 
10.000 
400 
230 
2000 
2100 
500 
200 
5.593 
3.210 
27.08 
29.9 
5.546 
2.293 
27.89 
27.91 
26.84 
29.20 
22.18 
22.93 
Average yield (%) ± SD (n=6)                                                                 26.16 ± 2.90 
 
Appendix 2: Extractable matter and solubility of A. afra FDAE 
 HCL (pH 1.2) Phosphate 
buffer (pH 6.8) 
Water 
Mass of FDAE (mg) 217.8 199.0 207.4 203.5 205.3 200.0 
Volume of solvent (ml) 5 5 5 5 5 5 
Mass of filter paper + 
residue (mg) 
834 816 811 822 868 1234 
Mass of filter paper (mg) 801 801 807 819 836 1220 
Mass of residue (mg) 33 15 4 3 32 14 
Extractable matter (mg/g) 848.5 844.8 980.7 985.3 844.1 930 
Mean ± SD (n=2) 846.6 ± 2.6 983.0 ± 3.2 888.0 ± 62 
Solubility mg/ml 37.0 36.8 40.7 40.1 34.7 37.2 
Mean ± SD 
(n=2) 
36.9 ± 0.1 40.4 ± 0.2 35.9 ± 1.8 
Parts 27.1 27.2 24.6 24.9 28.9 26.9 
 Mean ± SD  
(n=2) 
27.1 ± 0.1 24.8 ± 0.3 27.9 ± 1.4 
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Appendix 3: Residual moisture content of the A. afra freeze-dried aqueous extract 
powder 
 
Sample Mass of FDAE (g) Moisture content (%) 
1 0.153 2.63 
2 0.179 2.25 
3 0.206 2.44 
4 0.208 2.40 
5 0.152 2.65 
Average ± SD  
(n=5) 
 2.47 ± 0.15 
 
 
 
Appendix 4: Univariate ANOVA results for comparison of dissolution profiles of TFC 
and, free and total luteolin from FDAE of A. afra 
 
 p – value 
Time 
(minutes) 
Free versus total luteolin Free luteolin versus TFC Total luteolin versus 
TFC 
5 0.8681 0.3517 0.2897 
15 0.2243 0.1618 0.7856 
30 0.1564 0.0272 0.0484 
60 0.9182 0.7225 0.3252 
120 0.6540 0.8696 0.1882 
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Appendix 5: Fitting of A. afra FDAE and phytosomes dissolution data for mathematical 
modelling. Best fit values are highlighted. 
  
  
 
FDAE 
  
 
 
 
Phytosome 
 
Free luteolin 
 
Total luteolin 
 
TFC 
Mathematical Model Parameter 
Probit_2 
  
 
 
Α 
-3.687 -4.802 -4.369 -2.564 
Β 
4.071 5.517 5.144 4.129 
Fmax 
97.817 92.072 99.977 111.065 
AIC 
35.1920 32.1749 27.2665 48.8327 
 
Weibull_3 
 
    
Β 
1.454 2.422 2.103  2.377 
Fmax 
96.437 91.691 97.938 100.944 
AIC 
34.8151 32.4451 25.8831 49.3717 
 
 
Weibull_4 
 
 
Β 
1.112 1.286 2.407 2.188 
Ti 
-2.936 -1.499 -6.964 -0.493 
Fmax 
123.656 99.196 97.092 102.797 
AIC 
29.7699 29.3640 27.1701 47.7687 
 
Logistic 3 
  
 
K 
0.366 0.516 0.510  0.889 
Γ 
12.539 9.359 9.200 4.256 
Fmax 
94.512 91.926 97.332 99.654 
 
AIC 
34.8135 32.3540 25.4667 49.6077 
 
Peppas-Sahlin 1 with Tlag 
  
 
 
 
k1 
49.413 54.706 69.717  -604.597 
k2 
-21.669 -11.213 -16.990 617.251 
M 
0.621 0.371 0.327 0.387 
Tlag 
-0.446 4.060 3.638 1.163 
 
AIC 
28.6513 24.3334 24.2186 51.8195 
 
Peppas-Sahlin 2 with Tlag 
  
 
k1 
22.434 27.953 27.769  41.921 
k2 
-1.284 -1.883 -1.802 -2.753 
Tlag 
3.612 4.471 3.424 2.135 
AIC 
33.8283 34.9292 35.6259 50.5413 
 
First order with Fmax 
 
k1 
0.075 0.083 0.095  0.067 
Fmax 
98.143 95.375 99.433 216.613 
 
AIC 
35.0982 37.7048 35.6470  57.6354 
 
Makoid-Bakanar with 
Tlag 
 
 
kMB 
23.116 43.798 53.146  19.977 
N 
0.997 0.472 0.276 2.152 
K 
0.012 0.008 0.005 0.183 
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 Tlag 
-3.124 2.828 3.258 0.354 
AIC 
29.5818 24.2481 26.9513 48.0548 
 
Korsmeyer-Peppas 
  
 
 
    
kKP 
X X X  5.099 
N 
X X X 1.637 
R2 
X X X 0.9762 
R2adj 
X X X 0.9750 
AIC 
   100.2955 
 
Appendix 6: Preparation procedures for dissolution media 
Dissolution media Preparation procedure 
0.1 N HCL pH 1.2 9.6 ml of 32% w/v hydrochloric acid 
added to 500 ml of distilled water 
and then filled to 1 000 ml with 
distilled water. pH adjusted using 
either 2 N hydrochloric acid or 2 M 
NaOH. 
Phosphate buffer pH 6.8 Sodium dihydrogen phosphate 
dihydrate (7.8 g) and sodium 
dihydrogen phosphate-12-hydrate 
(17.9 g) dissolved in 500 ml of 
distilled water and then filled to 
1 000 ml with distilled water. pH 
adjusted using either 2 N 
hydrochloric acid or 2 M NaOH. 
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